What is aspergillus fumigatus allergy

Publikationen

Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, Röhmel J, Eschenhagen P, Grehn C, Seidel K, Rickerts V, Lozza L, Stervbo U, Nienen M, Babel N, Milleck J, Assenmacher M, Cornely OA, Ziegler M, Wisplinghoff H, Heine G, Worm M, Siegmund B, Maul J, Creutz P, Tabeling C, Ruwwe-Glösenkamp C, Sander LE, Knosalla C, Brunke S, Hube B, Kniemeyer O, Brakhage AA, Schwarz C, Scheffold A(2019)Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans.Cell 176(6), 1340-1355.e15.

DetailsPubMed

Ballard E, Weber J, Melchers WJG, Tammireddy S, Whitfield PD, Brakhage AA, Brown AJP, Verweij PE, Warris A(2019)Recreation of in-host acquired single nucleotide polymorphisms by CRISPR-Cas9 reveals an uncharacterised gene playing a role in Aspergillus fumigatus azole resistance via a non-cyp51A mediated resistance mechanism.Fungal Genet Biol 130, 98-106. DetailsPubMed

Blango MG, Kniemeyer O, Brakhage AA(2019)Conidial surface proteins at the interface of fungal infections.PLOS Pathogens 15(9), e1007939.

(Review) DetailsPubMed

Brakhage AA(2019)Gleichgewicht des Mikroversums.BIOspektrum 25(2), 229. (Review) Details

Brkljaca R, Dahse HM, Voigt K, Urban S(2019)Antimicrobial evaluation of the constituents isolated from Macropidia fuliginosa (Hook.) Druce.Natural Product Communications 14(10), 1-6. Details

Burow K, Grawunder A, Harpke M, Pietschmann S, Ehrhardt R, Wagner L, Voigt K, Merten D, Büchel G, Kothe E(2019)Microbiomes in an acidic rock-water cave system.FEMS Microbiol Lett 366(13), pii: fnz167. DetailsPubMedOpen Access

Dasari P, Koleci N, Shopova I, Wartenberg D, Beyersdorf N, Dietrich S, Sahagun-Ruiz A, Figge MT, Skerka C, Brakhage AA, Zipfel PF(2019)Enolase from Aspergillus fumigatus is a moonlighting and immune evasion protein that binds the human plasma complement proteins factor H, FHL-1, C4BP, and plasminogen.Front Immunol 10(2573), DetailsPubMedOpen AccessPDF

Hartung S, Rauh C, Hoang TNM, Jahreis S, Wagner K, Macheleidt J, Brakhage AA, Rummler S, Hochhaus A, von Lilienfeld-Toal M(2019)Fast and Quantitative Evaluation of Human Leukocyte Interaction with Aspergillus fumigatus Conidia by Flow Cytometry.Cytometry A 95(3), 332-338.

DetailsPubMed

Hassan MIA, Cseresnyes Z, Al-Zaben N, Dahse HM, Vilela de Oliveira RJ, Walther G, Voigt K, Figge MT(2019)The geographical region of origin determines the phagocytic vulnerability of Lichtheimia strains.Environ Microbiol 21(12), 4563-4581. DetailsPubMedOpen AccessPDFSupplement

Hassan MIA, Voigt K(2019)Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors.Med Mycol 57(Supplement_2), 245-256. (Review) DetailsPubMed

Featuring the work of recognized worldwide experts, this user-friendly text presents the most current scientific information, diagnostic approaches, and management strategies for the care of children with acute and chronic respiratory diseases.

A consistent chapter format enables you to rapidly and effortlessly locate the most current protocols on manifestations, etiologies, triggers, approaches to treatment, complications, and preventative strategies. And, a bonus website—new to this edition—features every of the book’s illustrations and extensive reference lists for each chapter in electronic format for your personal use.

  1. Organizes material to parallel your clinical decision making process.
  2. Provides expert guidance on what diagnostic tests to order for each patient—and how to interpret the results.

  3. Uses extensive color-coded algorithms to facilitate quick diagnosis, management, and treatment decisions.
  4. Includes guidance on differential diagnosis to assist you determine which disease or condition your patient may own.
  5. Presents significant “take home concepts within each chapter to assist you recall clinical pearls.
  6. Includes the most need-to-know basic science, focusing on providing clear implications for patient care.
  1. Provides the latest scientific information and diagnostic and management strategies for the care of children with respiratory illnesses.

  2. Features a new, functional four-color design to assist you identify significant information quickly and differentiate between essential and extraneous material.
  3. Includes a separate website with every of the images from the text and extensive reference lists—downloadable for your personal use.
  4. Presents cutting-edge coverage with new information on the biology of, and the influences on, the respiratory system during childhood, as well as the diagnosis and management of both common (ie, wheezing baby, cystic fibrosis, tuberculosis) and less common (ie, SARS, chest tumors, collagen vascular diseases, Familial Mediterranean Fever) conditions.

Featuring the work of recognized worldwide experts, this user-friendly text presents the most current scientific information, diagnostic approaches, and management strategies for the care of children with acute and chronic respiratory diseases.

A consistent chapter format enables you to rapidly and effortlessly locate the most current protocols on manifestations, etiologies, triggers, approaches to treatment, complications, and preventative strategies. And, a bonus website—new to this edition—features every of the book’s illustrations and extensive reference lists for each chapter in electronic format for your personal use.

  1. Organizes material to parallel your clinical decision making process.
  2. Provides expert guidance on what diagnostic tests to order for each patient—and how to interpret the results.

  3. Uses extensive color-coded algorithms to facilitate quick diagnosis, management, and treatment decisions.
  4. Includes guidance on differential diagnosis to assist you determine which disease or condition your patient may own.
  5. Presents significant “take home concepts within each chapter to assist you recall clinical pearls.
  6. Includes the most need-to-know basic science, focusing on providing clear implications for patient care.
  1. Provides the latest scientific information and diagnostic and management strategies for the care of children with respiratory illnesses.

  2. Features a new, functional four-color design to assist you identify significant information quickly and differentiate between essential and extraneous material.
  3. Includes a separate website with every of the images from the text and extensive reference lists—downloadable for your personal use.
  4. Presents cutting-edge coverage with new information on the biology of, and the influences on, the respiratory system during childhood, as well as the diagnosis and management of both common (ie, wheezing baby, cystic fibrosis, tuberculosis) and less common (ie, SARS, chest tumors, collagen vascular diseases, Familial Mediterranean Fever) conditions.

Voransicht des Buches »

Featuring the work of recognized worldwide experts, this user-friendly text presents the most current scientific information, diagnostic approaches, and management strategies for the care of children with acute and chronic respiratory diseases.

A consistent chapter format enables you to rapidly and effortlessly locate the most current protocols on manifestations, etiologies, triggers, approaches to treatment, complications, and preventative strategies. And, a bonus website—new to this edition—features every of the book’s illustrations and extensive reference lists for each chapter in electronic format for your personal use.

  1. Organizes material to parallel your clinical decision making process.
  2. Provides expert guidance on what diagnostic tests to order for each patient—and how to interpret the results.
  3. Uses extensive color-coded algorithms to facilitate quick diagnosis, management, and treatment decisions.

  4. Includes guidance on differential diagnosis to assist you determine which disease or condition your patient may own.
  5. Presents significant “take home concepts within each chapter to assist you recall clinical pearls.
  6. Includes the most need-to-know basic science, focusing on providing clear implications for patient care.
  1. Provides the latest scientific information and diagnostic and management strategies for the care of children with respiratory illnesses.
  2. Features a new, functional four-color design to assist you identify significant information quickly and differentiate between essential and extraneous material.

  3. Includes a separate website with every of the images from the text and extensive reference lists—downloadable for your personal use.
  4. Presents cutting-edge coverage with new information on the biology of, and the influences on, the respiratory system during childhood, as well as the diagnosis and management of both common (ie, wheezing baby, cystic fibrosis, tuberculosis) and less common (ie, SARS, chest tumors, collagen vascular diseases, Familial Mediterranean Fever) conditions.

Aspergillus fumigatus has become one of the most significant fungal human pathogens in industrialized countries.

It causes diverse diseases love allergic bronchopulmonary aspergillosis, aspergilloma, and invasive aspergillosis depending on the underlying disease as well as the immunological status of the host. A. fumigatus is today one of the most threatening aerial fungal pathogens because nosocomially acquired invasive aspergillosis typically occurs in the treatment setting for hematological malignancy. With the increasing number of immuno-compromised individuals such as AIDS and cancer patients or transplant recipients, systemic Aspergillus infections are often life-threatening with a extremely high mortality rate even after anti-mycotic therapy.

This book provides a comprehensive overview of the classical and molecular techniques used in the isolation, analysis, diagnosis, and the identification of potential virulence factors of A. fumigatus. The pathogenesis and clinical presentation, the epidemiology and the therapy of A. fumigatus infections are discussed extensively. Compiling the most up-to-date information available, this volume will be a useful reference source for both clinical investigators and basic research scientists.

Donald Hoffman, Henning Lowenstein, David G. Marsh,
Thomas A.E. Platts-Mills and Wayne Thomas

This article was first published in the Bulletin of the World Health Organization,
72(5):796-806 (1994), and is reproduced here by permission.

Minor corrections were made here. There are no reprints available.

A. Introduction.

Rapid advances own been made in the past few years on allergen characterizationand sequence determination by chemical and molecular biological approaches.

This is indicated by the list of allergens with known partial or finish amino acid sequences in Table 1. A number of other significant allergens are known in addition to those in Table 1 but their sequences are as yet not known.

A useful source for known allergens is the Allergen Database (ALBE) in which are compiled their known biochemical and immunological properties together with their
sequence data if known (1).

To take into account these advances, a revision of the current allergen
nomenclature system (2) is given under. As in the current nomenclature system,
the proposed revisions are for allergens which induce IgE-mediated (atopic) allergy in humans. In addition to the expected thorough immunochemical characterization of any newly discovered allergen, investigators are urged to obtain partial, or preferably finish, sequence data before using the official nomenclature system.

Also it is expected that investigators would screen a reasonable population size so as to establish the frequency of response in patients to the newly discovered allergens. (Investigators are invited to consult our committee members for assigning an allergen number before publication so as to avoid duplication).
Investigators frequently refer to allergens as major or minor ones. The
generally accepted meaning of this terminology is that an allergen is designated as either major or minor depending on whether greater or less than 50% of  patients tested own the corresponding allergen-specific IgEs (cf.

3-5).
The revised nomenclature for allergens is given under together with the
proposed nomenclatures for (a) allergen genes, mRNAs and cDNAs and (b) recombinant and synthetic peptides of allergenic interest.

B. Revised Allergen Nomenclature.

1. Allergens.

Allergens are designated according to the accepted taxonomic name of their source as follows: the first three letters of the genus, space, the first letter  of the species, space, and an Arabic number. The numbers are assigned to the allergens in the order of their identification, and the same number is generally used to designate homologous allergens of related species.

As two examples, Lol p 1 refers to the first pollen allergen identified from Lolium perenne, rye grass, and Cyn d 1 refers to the homologous pollen allergen from Cynodon dactylon, Bermuda grass.
In some instances, the above system of the first 3 letters of a genus and the first letter of a species has to be modified to include an additional letter for designation of the exact genus or species. For example, 4 of the numerous vespids which can cause insect allergy are Vespula vulgaris, Vespula vidua, Vespula consobrina and Vespa crabo.

The homologous major venom allergens, antigen 5s, from Vespula vulgaris and Vespula vidua are both designated as Ves v 5 in the existing nomenclature, and those from Vespula consobrina and Vespa crabo are designated as Ves c 5. To avoid these ambiguities, antigen 5s from Vespula vulgaris and Vespula vidua will be designated as Ves v 5 and Ves vi 5 respectively, and those from Vespula consobrina and Vespa crabo as Ves c 5 and Vesp c 5. In the examples given, the modified nomenclature is used for the allergens from Vespula vidua and Vespa crabo, as the allergens from Vespula vulgaris were characterized prior to those for Vespula vidua and Vespa crabo.

Another example is for allergens from the domestic dog (Canis domesticus) and the mold Candida albicans. To avoid ambiguity, the modified system is used to designate Can d and Cand a allergens from these two sources respectively.
In the current nomenclature system (2) the letters are italicized and the numerals are Roman numerals. In the revised system, only letters of normal type and Arabic numbers are used. The proposed changes conform to the accepted nomenclature used in bacterial genetics (6) and HLA system (7) in that italicized and normal characters are used to represent genotypes and phenotypes respectively. Allergens are designated according

2.

Allergens and isoallergens.

An allergen from a single species may consist of several closely similar
molecules. These similar molecules are designated as isoallergens when they share the following common biochemical properties:
  a. similar molecular size
  b. identical biological function, if known, e.g. enzymatic action
  c. > 67% identity of amino acid sequences.

It is recognized that the recommended > 67% sequence identity for 2 allergens to be assigned to the same group is only a guide. There are likely to be borderline cases. As an example, the ragweed allergens Amb a 1 and 2 share 65% amino acid sequence identity (8). These allergens were assigned to diverse groups because of their diverse immunochemical properties before their sequences were known.

Allergens from diverse species of the same or diverse genus which share the above-mentioned common biochemical properties are considered to belong to the same group and the sequence identity requirement can be < 67% as is the case for allergens of the same species. For example, Amb a 5 and Amb t 5 from short and giant ragweed pollens own about 45% sequence identity (9), and also own similar tertiary structures (10, 11). Another example is the minor pollen allergens Amb a 10, Poa p 10 and Lol p 10 from ragweed (12), Kentucky bluegrass (13) and rye grass (14).
Although their sequences are not known, they are assigned to the same allergen group as they clearly own the same biological function of cytochrome c.

3. Isoallergens and variants.

cDNA cloning of allergens often show nucleotide mutations which are either silent or which can lead to single or multiple amino acid substitutions. In the revised system, members of an allergen group which own > 67% amino acid sequence identity are designated as isoallergens. Each isoallergen may own multiple forms of closely similar sequences, which are designated as variants.
Isoallergens and their variants belonging to the same allergen group are designated by suffixes of a period followed by four Arabic numerals. The first two numerals 01 to 99 refer to a specific isoallergen, and the two subsequent numerals 01 to 99 refer to a specific variant of a specific isoallergen designated by the preceding two numerals.

In cases where there is only one known isoallergen but there are several variants, the system of a suffix of 4 numerals will still apply. These numerals will be chosen in the order of the identification of allergens and/or their cDNAs irrespective of the physicochemical properties of the allergens. In cases of silent mutations, there can be more than one suffix of 4 numerals designating the same allergen and in that case the suffix with the lowest number will be used to designate the allergen of interest.

The addition of suffixes of 4 numerals to designate isoallergens and their variants will permit their unambiguous designation. In numerous cases it is unnecessary to specify the isoallergen or variant and the corresponding suffixes may be deleted; e.g. Bet v 1 represents any Bet v 1 allergen and Bet v 1.0101 represents variant number 1 of isoallergen Bet v 1. Two other examples of this nomenclature system are given under.
On cDNA cloning, Amb a I showed multiple polymorphic forms which differ from each other by 12-24% in their sequences (8).

Four such forms of Amb a I are known and they are designated as Amb a 1.01, 1.02, 1.03 and 1.04. Each isoallergen of the Amb a I group is found to own 1 to 3 variants with > 97% of&n sequence identity. These variants of the Amb a 1.01 group will be designated as Amb a 1.0101, 1.0102 and etc.
In contrast to Amb a I, only two forms of Amb a II were found on cDNA cloning. These forms differ in two polymorphic sites and they own > 99% amino acid sequence identity. They are designated as Amb a 2.0101 and 2.0102.

C. Nomenclature for allergen genes, mRNAs and cDNAs.

At present the genomic structures of allergens are known in at least two cases; cat allergen Fel d 1 and mouse urinary allergen Mus m 1. Knowledge of the genomic structure can provide an understanding of how the diverse polymorphic forms are generated by differential splicing and/or exon usage. By adopting the revised nomenclature for allergens, we can reserve the italicized characters to designate an allergen gene. Normal characters are used for designation of mRNAs and cDNAs.
For example, Fel d 1 is a protein consisting of two polypeptide chains (15) which are encoded by two separate genes (16).

The two allergen genes for chains 1 and 2 of Fel d 1 will be represented by Fel d 1A and Fel d 1B respectively.
Allelic forms of mRNAs and cDNAs of the Fel d 1A gene are designated as mRNA or cDNA Fel d 1A.0101 where the numerals are to correspond to those of the polymorphic allergens.

D. Nomenclature for recombinant and synthetic peptides of allergenic interest.

There is interest in the possible use of fragments of allergens as reagents to modulate allergen-specific immune responses. Such fragments may be prepared by recombinant technology or by chemical synthesis.

Therefore it is useful to establish a generally accepted nomenclature for such peptides of allergenic interest.
The nomenclature for recombinant and synthetic peptides of allergenic interest is to be based on the nomenclature for naturally occurring allergens since it is well accepted by the scientific and the clinical communities.
An allergen which is prepared by recombinant (r) or chemical synthetic (s) means is to be differentiated from a natural (n) allergen by the addition of the prefix of r or s followed by a suffix of the amino acid residue positions which are given in parenthesis.

For examples, a recombinant hornet venom allergen Dol m 5.0201 which contains the entire sequence of 204 residues will be designated as rDol m 5.0201, and a recombinant or synthetic peptide of residue 151-165 of Dol m 5.0201 will be designated as r or sDol m 5.0201 (151-165) respectively.
Natural allergens may contain post-translational modifications as numerous proteins do. These modifications include glycosylation, acylation, methylation and etc. Recombinant or synthetic allergen, designated by the prefix r or s, is taken to indicate that it does not contain the post-translational modification of the natural allergen.

If the recombinant or synthetic allergen does contain the exact same modification as that of the natural allergen, it will be designated with a prefix of rn or sn. For example, the honey bee venom allergen phospholipase A2, Api m 1, is a glycoprotein with an oligosaccharide attached at the asparagine residue number 13 (17, 18). A synthetic peptide of residues 1-20 of Api m 1 without the oligosaccharide at residue 13 will be designated as sApi m 1 (1-20), and a synthetic peptide of residue 1-20 with the exact same oligosaccharide of the natural allergen will be designated as snApi m 1 (1-20).
For recombinant or synthetic fragments which are derivatives of sequences contained within the native allergen structure, an additional suffix enclosed in square brackets will be used to indicate that the peptide referred to is an analogue.

Substitutions or modifications of amino acid residues are given with the standard one-letter code and superscript numbers indicate the residue positions at which modifications happen. The one-letter codes for L-amino acids are given in upper case letters and those for D-amino acids are in lower case letters.
The modifications which can be substitution, insertion or deletion are specified in parenthesis within the brackets. Obviously when there are numerous changes, it will not be practical to follow this nomenclature but to give the fully modified sequences.

Examples of these analogs of sDol m 5.0201 (151-165) are given below:

  1. Insertion: sDol m 5.0201 (151-165) [+K 153] — one residue of L-lysine is inserted between positions 153-154
  2. Deletion: sDol m 5.0201 (151-165) [-K 153] — L-lysine residue at position 153 is deleted
  3. Substitution: sDol m 5.0201 (151-165) [k 153] — L-lysine residue at position 153 of sDol m 5.0201 (151-165) is substituted with D-lysine
  4. Unmodified: sDol m 5.0201 (151-165)
  5. N-terminal modification: sDol m 5.0201 (151-165) [N-Ac] — N-terminal amino group is acetylated
  6. C-terminal modification: sDol m 5.0201 (151-165) [C-NH2] — C-terminal carboxyl group is in the form of carboxamide

The nomenclature proposed above is extremely similar to that used for synthetic pe ptides representative of immunoglobulin sequences (19).

E. Acknowledgment

We thank Drs. Martin Chapman, Irwin Griffith, Shyam Mohapatra,
Rodriguez and Alec Sehon for reviewing this document.

Table 1

Some allergens with known sequences

Allergen source MW seq.
Systematic name Former name(s) kDa data References
A. Weed pollens.
Asterales Ambrosia artemisiifolia (short ragweed)
Amb a 1 antigen E 38 c 8, 20
Amb a 2 antigen K 38 c 8, 21
Amb a 3 Ra3 11 c 22
Amb a 5 Ra5 5 c 11, 23
Amb a 6 Ra6 10 c 24, 25
Amb a 7 Ra7 12 p 26
Amb a ? 11 c 27
Ambrosia trifida (giant ragweed)
Amb t 5 Ra5G 4.4 c 9, 10, 28
Artemisia vulgaris (mugwort)
Art v 2 35 p 29
Allergen source MW seq.
Systematic name Former name(s) kDa data References
B.

Grass pollens.

Poales Cynodon dactylon (Bermuda grass)
Cyn d 1 32 c 30, 31
Dactylis glomerata (orchard grass)
Dac g 1 AgDg1 32 p 32
Dac g 2 11 c 33
Dac g 5 31 p 34
Lolium perenne (rye grass)
Lol p 1 group I 27 c 35, 36
Lol p 2 group II 11 c 37
Lol p 3 group III  11 c 38
Lol p 5 31 p 34
Lol p 9 Lol p Ib 31/35 c 39
Phleum pratense (timothy grass)
Phl p 1 27 c 40, 41
Phl p 5 Ag25 32 c 42, 43, 44, 45
Poa pratensis (Kentucky blue grass)
Poa p 1 group I 33 p 46
Poa p 5 31 p 34
Poa p 9 32/34 c 47
Sorghum halepense (Johnson grass)
Sor h 1 c 48
Allergen source MW seq.
Systematic name Former name(s) kDa data References
C.

Tree pollens.

Fagales Alnus glutinosa (alder)
Aln g 1 17 c 49
Betula verrucosa (birch)
Bet v 1 17 c 50
Bet v 2 profilin 15 c 51
Carpinus betulus (hornbeam)
Car b 1 17 c 52
Corylus avellana (hazel) 
Cor a 1 17 c 53
Quercus alba (white oak)
Que a 1 17 p 54
Pinales Cryptomeria japonica (sugi)
Cry j 1 41-45 c 55, 56
Cry j 2 c 57, 58
Juniper sabinoides (mountain cedar)
Jun s 1 50 c 59
Juniper virginiana (eastern red cedar) 
Jun v 1 45-50 c 58
Oleales Olea europea (olive)
Ole e 1 16 c 59, 60
Allergen source MW seq.
Systematic name Former name(s) kDa data References
D.

Mites.

Dermatophagoides pteronyssinus (mite)
Der p 1 antigen P1 25 c 61
Der p 2 14 c 62
Der p 3 trypsin 28/30 p 63
Der p 4 amylase 60 p 64
Der p 5 14 c 65
Der p 6 chymotrypsin 25 p 66
Der p 7 22-28 c 67
Dermatophagoides microceras (mite)
Der m 1 25 p 68
Dermatophagoides farinae (mite)
Der f 1 25 c 69
Der f 2 14 c 70, 71
Der f 3 30 p 72
Lepidoglyphus destructor (storage mite)
Lep d ? 15 p 73
Allergen source MW seq.
Systematic name Former name(s) kDa data References
E.

Animals.

Canis familiaris (dog)
Can f 1 25 c 74, 75
Can f 2 27 c 74, 75
Felis domesticus (cat saliva)
Fel d 1 cat-1 38 c 15
Mus musculus (mouse urine)
Mus m 1 MUP 19 c 76, 77
Rattus norvegius (rat urine) 
Rat n 1 17 c 78, 79
Allergen source MW seq.
Systematic name Former name(s) kDa data References
F.

Fungi.

Aspergillus fumigatus
Asp f 1 18 c 80
Asp f ? 90 p 81
Asp f ? 55 p 82
Candida albicans
Cand a ? 40 c 83
Alternaria alternata
Alt a 1 28 p 84, 85, 86
Trichophyton tonsurans
Tri t 1 30 p 87
Allergen source MW seq.

Systematic name Former name(s) kDa data References
G. Insects.
Apis mellifera (honey bee)
Api m 1 phospholipase A2 16 c 88
Api m 2 hyaluronidase  44 c 89
Api m 4 melittin 3 c 90
Bombus pennsylvanicus (bumble bee) 
Bom p 1 phospholipase 16 p 91
Bom p 4 protease p 91
Blattaria germanica (cockroach)
Bla g 2 20 c 92
Chironomus thummi thummi (midges)
Chi t 1 hemoglobin 16 c 93
Dolichovespula maculata (white face hornet)
Dol m 1 phospholipase A1 35 c 94
Dol m 2 hyaluronidase  44 c 95
Dol m 5 antigen 5 23 c 96, 97
Dolichovespula arenaria (yellow hornet) 
Dol a 5 antigen 5 23 c 98
Polistes annularis (wasp)
Pol a 1 phospholipase A1 35 p 99
Pol a 2 hyaluronidase 44 p 99
Pol a 5 antigen 5 23 c 98
Polistes exclamans (wasp)
Pol e 1 phospholipase A1 34 p 101
Pol e 5 antigen 5 23 c 98
Polistes fuscatus (wasp)
Pol f 5 antigen 5 23 c 100
Polistes metricus (wasp)
Pol m 5 antigen 5 23 p 100
Vespula flavopilosa (yellowjacket) 
Ves f 5 antigen 5 23 c 100
Vespula germanica (yellowjacket)
Ves g 5 antigen 5 23 c 100
Vespula maculifrons (yellowjacket)
Ves m 1 phospholipase A1 33.5 c 102
Ves m 2 hyaluronidase 44 p 103
Ves m 5 antigen 5 23 c 98
Vespula pennsylvanica (yellowjacket)
Ves p 5 antigen 5 23 c 100
Vespula squamosa (yellowjacket)
Ves s 5 antigen 5 23 c 100
Vespula vidua (wasp) 
Ves vi 5 23 c 100
Vespula vulgaris (yellowjacket)
Ves v 1 phopholipase A1 35 c 99
Ves v 2 hyaluronidase 44 p 99
Ves v 5 antigen 5 23 c 98
Vespa crabo (European hornet)
Vesp c 1 phospholipase 34 p 101
Vesp c 5 antigen 5 23 c 100
Solenopsis invicta (fire ant)
Sol i 2 13 c 104, 105
Sol i 3 24 c 104
Sol i 4 13 c 104
Allergen source MW seq.
Systematic name Former name(s) kDa data References
H.

Foods.

Gadus Callarias (cod)
Gad c 1 allergen M 12 c 106
Gallus domesticus (chicken)
Gal d 1 ovomucoid 28 c 107, 108
Gal d 2 ovalbumin 44 c 107, 108
Gal d 3 conalbumin(Ag22) 78 c 107, 108
Gal d 4 lysozyme 14 c 107, 108
Penaeus aztecus (shrimp)
Pen a 1 tropomyosin 36 p 109
Penaeus indicus (shrimp)
Pen i 1 tropomyosin 34 c 110
Brassica juncea (oriental mustard)
Bra j 1 25 albumin  14 c 111
Hordeum vulgare (barley)
Hor v 1 BMAI-1 15 c 112
Sinapis alba (yellow mustard)
Sin a 1 25 albumin 14 c 113
Allergen source
Systematic name Former name(s) References
I.

Others.

Ascaris suum (worm)
Asc s 1 10 p 114
Hevea brasiliensis (rubber) 
Hev b1  elongation factor 58 p 115

References refer to those where partial (P) or finish (C) sequence data are available. The original references describing the initial characterization studies are not given because of limited space. Also we apologize to our colleagues whose allergen sequence data we may own overlooked, or whose publications appeared after Dec., 1993, for inclusion in this table.

Sequence data for group 5 and 9 allergens from several grass pollens indicate that they are highly homologous proteins. Comparison of finish sequencedata of group 5 and 9 allergens from a single grass species will clarify whether these two groups are the same protein.

References

1. Marsh, D.G., and L.R. Freidhoff. 1992. ALBE, an allergen database. IUIS, 

Baltimore, MD, Edition 1.0.

2. Marsh, D.

G., L.

What is aspergillus fumigatus allergy

Goodfriend, T. P. King, H. Lowenstein, and T. A. E. Platts-

Mills. 1986. Allergen nomenclature. Bull WHO 64:767-770.

3. King, T.P., P.S. Norman, and J.T. Cornell. 1964. Isolation and 

characterization of allergen from ragweed pollen. II. Biochemistry 3:458-468.

4. Lowenstein, H. 1980. Timothy pollen allergens. Allergy 35:188-191.

5. Aukrust, L. 1980. Purification of allergens in Cladosporium herbarum.
Allergy 35:206-207.

6. Demerec, M., E. A. Adelberg, A. J. Clark, and P. E. Hartman. 1966. A 

proposal for a uniform nomenclature in bacterial genetics.

Genetics 54:61-75.

7. Bodmer, J. G., E. D. Albert, W. F. Bodmer, B. Dupont, H. A. Erlich, B.

Mach, S. G. E. Marsh, W. R. Mayr, P. Parham, T. Sasuki, G. M. Th.

Schreuder, J. L. Strominger, A. Svejgaard, and P. I. Terasaki. 1991.

Nomenclature for factors of the HLA system, 1990. Immunogenetics 33:301-309.

8. Griffith, I.J., J. Pollock, D.G. Klapper, B.L. Rogers, and A.K. Nault. 1991.

Sequence polymorphism of Amb a I and Amb a II, the major allergens in 

Ambrosia artemisiifolia (short ragweed). Int. Arch. Allergy Appl. Immunol.

96:296-304.

9. Roebber, M., D. G. Klapper, L. Goodfriend, W.

B. Bias, S. H. Hsu, and D.
G. Marsh. 1985. Immunochemical and genetic studies of Amb t V (Ra5G), an Ra5
homologue from giant ragweed pollen. J. Immunol. 134:3062-3069.

10. Metzler, W. J., K. Valentine, M. Roebber, M. Friedrichs, D. G. Marsh, and 

L. Mueller. 1992. Solution structures of ragweed allergen Amb t V. Biochemistry 

31:5117-5127.

11. Metzler, W. J., K. Valentine, M. Roebber, D. G. Marsh, and L. Mueller.

1992. Proton resonance assignments and three-dimensional solution structure of 

the ragweed allergen Amb a V by nuclear magnetic resonance spectroscopy.

Biochemistry 31:8697-8705.

12. Goodfriend, L., A.M. Choudhury, J. Del Carpio, and T.P. King. 1979.

Cytochromes C: New ragweed pollen allergens. Fed. Proc. 38:1415.

13. Ekramoddoullah, A. K. M., F. T. Kisil, and A. H. Sehon. 1982. Allergenic 

cross reactivity of cytochrome c from Kentucky bluegrass and perennial ryegrass 

pollens. Mol. Immunol. 19:1527-1534.

14. Ansari, A. A., E. A. Killoran, and D. G. Marsh. 1987. An investigation
of human response to perennial ryegrass (Lolium perenne) pollen cytochrome c 

(Lol p X). J. Allergy Clin. Immunol. 80:229-235.

15.

Morgenstern, J.P., I.J. Griffith, A.W. Brauer, B.L. Rogers, J.F. Bond, M.D.

Chapman, and M. Kuo. 1991. Amino acid sequence of Fel d I, the major allergen 

of the domestic cat: protein sequence analysis and cDNA cloning. Proc. Natl.
Acad. Sci. USA 88:9690-9694.

16. Griffith, I.J., S. Craig, J. Pollock, X. Yu, J.P. Morgenstern, and B.L.
Rogers. 1992. Expression and genomic structure of the genes encoding FdI, the
major allergen from the domestic cat.

Gene 113:263-268.

17. Weber, A., L. Marz, and F. Altmann. 1986. Characteristics of the asparagine-

linked oligosaccharide from honey-bee venom phospholipase A2. Comp. Biochem.

Physiol. 83B:321-324.

18. Weber, A., H. Schroder, K. Thalberg, and L. Marz. 1987. Specific 

interaction of IgE antibodies with a carbohydrate epitope of honey bee venom 

phospholipase A2. Allergy 42:464-470.

19. Stanworth, D. R., K. J. Dorrington, T. E. Hugli, K. Reid, and M. W. Turner.

1990. Nomenclature for synthetic peptides representative of immunoglobulin
chain sequences.

Bulletin WHO 68:109-111.

20. Rafnar, T., I. J. Griffith, M. C. Kuo, J. F. Bond, B. L. Rogers, and D.
G. Klapper. 1991. Cloning of Amb a I (Antigen E), the major allergen family of
short ragweed pollen. J. Biol. Chem. 266: 1229-1236.

21. Rogers, B.L., J.P. Morgenstern, I.J. Griffith, X.B. Yu, C.M. Counsell, A
.W. Brauer, T.P. King, R.D. Garman, and M.C. Kuo. 1991. Finish sequence 

of the allergen Amb a II: recombinant expression and reactivity with T cells from 

ragweed allergic patients. J.

Immunol. 147:2547-2552.

22. Klapper, D.G., L. Goodfriend, and J.D. Capra. 1980. Amino acid sequence 

of ragweed allergen Ra3. Biochemistry 19:5729-5734.

23. Ghosh, B., M.P. Perry, T. Rafnar, and D.G. Marsh. 1993. Cloning and 

expression of immunologically athletic recombinant Amb a V allergen of short 

ragweed (Ambrosia artemisiifolia) pollen. J. Immunol. 150:5391-5399.

24. Roebber, M., R. Hussain, D. G. Klapper, and D. G. Marsh. 1983. Isolation 

and properties of a new short ragweed pollen allergen, Ra6.

J. Immunol.

131:706-711.

25. Lubahn, B., and D.G. Klapper. 1993. Cloning and characterization of 

ragweed allergen Amb a VI (abst). J. Allergy Clin. Immunol. 91:338.

26. Roebber, M., and D.G. Marsh. 1991. Isolation and characterization of 

allergen Amb a VII from short ragweed pollen. J. Allergy Clin. Immunol. 87:324.

27. Rogers, B.L., J. Pollock, D.G. Klapper, and I.J. Griffith. 1993. Cloning, 

complete sequence, and recombinant expression of a novel allergen from short
ragweed pollen (abst).

J. Allergy Clin. Immunol. 91:339.

28. Goodfriend, L., A.M. Choudhury, D.G. Klapper, K.M. Coulter, G. Dorval, J.
DelCarpio, and C.K. Osterland. 1985. Ra5G, a homologue of Ra5 in giant 

ragweed pollen: isolation, HLA-DR-associated activity and amino acid sequence.

Mol. Immunol. 22:899-906.

29. Nilsen, B. M., K. Sletten, M. O’Neill, B. Smestead Paulsen, and H. van 

Halbeek. 1991. Structural analysis of the glycoprotein allergen Art v II from 

pollen of mugwort (Artemesia vulgaris).

J. Biol. Chem. 266:2660-2668.

30. Matthiesen, F., M. Schumacher, and H. Lowenstein. 1991. Characterization 

of the major allergen of Cynodon dactylon (Bermuda grass) pollen. J. Allergy
Clin. Immunol. 88:763-774.

31. Smith, P.M., M.B. Singh, and R.B. Knox. 1993. Characterization and 

cloning of the major allergen of Bermuda grass, Cyn d I. In: «Molecular Biology and
Immunology of Allergens» (D. Kraft and A. Sehon, eds.). CRC Press, Boca Raton.
pp. 157-160.

32. Mecheri, S., G. Peltre, and B. David.

1985. Purification and characterization 

of a major allergen from Dactylis glomerata pollen: The Ag Dg 1. Int. Arch.

Allergy Appl. Immunol. 78:283-289.

33. Roberts, A.M., L.J. Bevan, P.S. Flora, I. Jepson, and M.R. Walker. 1993.

Nucleotide sequence of cDNA encoding the Group II allergen of Cocksfoot/

Orchard grass (Dactylis glomerata), Dac g II. Allergy 48:615-623.

34. Klysner, S., K. Welinder, H. Lowenstein, and F. Matthiesen. 1992. Group 

V allergens in grass pollen IV. Similarities in amino acid compositions and amino 

terminal sequences of the group V allergens from Lolium perenne, Poa pratensis 

and Dactylis glomerata.

Clin. Exp. Allergy 22: 491-497.

35. Perez, M., G. Y. Ishioka, L. E. Walker, and R. W. Chesnut. 1990. cDNA
cloning and immunological characterization of the rye grass allergen Lol p I.

J. Biol. Chem. 265:16210-16215.

36. Griffith, I. J., P. M. Smith, J. Pollock, P. Theerakulpisut, A. Avjioglu, 

S. Davies, T. Hough, M. B. Singh, R. J. Simpson, L. D. Ward, and R. B. Knox.

1991. Cloning and sequencing of Lol p I, the major allergenic protein of rye-

grass pollen. FEBS Letters 279:210-215.

37. Ansari, A. A., P. Shenbagamurthi, and D.G. Marsh. 1989. Finish amino
acid sequence of a Lolium perenne (perennial rye grass) pollen allergen, Lol p II.

J. Biol. Chem. 264:11181-11185.

38. Ansari, A. A., P. Shenbagamurthi, and D. G. Marsh. 1989. Complete 

primary structure of a Lolium perenne (perennial rye grass) pollen allergen, Lol p I
II: Comparison with known Lol p I and II sequences. Biochemistry 28:8665-8670.

39. Singh, M. B., T. Hough, P. Theerakulpisut, A. Avjioglu, S. Davies, P. M.
Smith, P. Taylor, R. J. Simpson, L. D. Ward, J. McCluskey, R. Puy, and R.B.

Knox. 1991. Isolation of cDNA encoding a newly identified major allergenic protein 

of rye-grass pollen: Intracellular targeting to the amyloplost.

Proc. Natl. Acad.

Sci. 88:1384-1388.

40. Matthiesen, F., A.K. Nielsen, T.J. Sogaard, S. Klysner, and H. Lowenstein.

1992. NH2-terminal sequences of four immunoaffinity purified grass pollen 

allergens: Phl p I, Poa p I, Sec c I and Cyn d I (abst.). Allergy (Supp.) 47:31.

41. Laffer, S., S. Vrtala, D. Kraft, and O. Scheiner. 1992. cDNA cloning of 

a major allergen of rye (Secale cereale) and timothy grass (Phleum pratense).
XVth Eur.

Congress of Allergology and Clin. Immunol. Paris.

42. Matthiesen, F., and H. Lowenstein. 1991. Group V allergens in grass 

pollens. I. Purification and characterization of the group V allergen from Phleum
pratense pollen, Phl p V. Clin. Exp. Allergy 21:297-307.

43. Vrtala, S., S. Laffler, M. Duchene, D. Kraft, O. Scheiner, and R. Valenta.

1992. cDNA cloning of a major grass pollen allergen from timothy grass 

(Phleum pratense): identification as Phl p V, a protein with possible targeting to 

the amyloplast. XVth Eur.

Congress of Allergology and Clin. Immunol. Paris.

44. Petersen, A., W.M. Becker, and M. Schlaak. 1992. Characterization of 

isoforms of the major allergen Phl p V by immunoblotting and microsequencing.

Int. Arch. Allergy Immunol. 98:105-109.

45. Bufe, A., W.M. Becker, A. Peterson, G. Schramm and M. Schlaak. 1993.

Partial mRNA sequence of Phl p V. EMBL accession number X70942.

46. Esch, R. E., and D. G. Klapper. 1989. Isolation and characterization of 

a major cross-reactive grass group I allergenic determinant.

Mol. Immunol. 26
:557-561.

47. Olsen, E., L. Zhang, R. D. Hill, F. T. Kisil, A. H. Sehon, and S.

Mohapatra. 1991. Identification and characterization of the Poa p IX group 

of basic allergens of Kentucky bluegrass pollen. J. Immunol. 147:205-211.

48. Avjioglu, A., M. Singh, and R.B. Knox. 1993. Sequence analysis of Sor
h I, the group I allergen of Johnson grass pollen and it comparison to rye-grass
Lol p I (abst). J. Allergy Clin. Immunol. 91:340.

49. Breiteneder, H., F. Ferreira, A. Reikerstorfer, M. Duchene, R. Valenta,
K. Hoffmann-Sommergruber, C. Ebner, M. Breitenbach, D.

Kraft, and O. Scheiner.

1992. Complementary DNA cloning and expression in Escherichia coli of Aln g I, 

the major allergen in pollen of alder (Alnus glutinosa). J. Allergy Clin. Immunol.

90:909-917.

50. Breiteneder, H., K. Pettenburger, A. Bito, R. Valenta, D. Kraft, H. Rumpold,

O. Scheiner, and M. Breitenbach. 1989. The gene coding for the major birch 

pollen allergen Bet v I is highly homologous to a pea disease resistance response 

gene.

EMBO J. 8:1935-1938.

51. Valenta, R., M. Duchene, C. Ebner, P. Valent, C. Sillaber, P. Deviller,
F. Ferreira, M. Tejkl, H. Edelmann, D. Kraft, and O. Scheiner. 1992. Profilins
constitute a novel family of functional plant pan-allergens. J. Exp. Med. 175:3
77-385.

52. Larsen, J.N., P. Stroman, and H. Ipsen. 1992. PCR based cloning and 

sequencing of isogenes encoding the tree pollen major allergen Car b I from 

Carpinus betulus, hornbeam.

Mol. Immunol. 29:703-711.

53. Breiteneder, H., F. Ferreira, K. Hoffman-Sommergruber, C. Ebner, M.

Breitenbach, H. Rumpold, D. Kraft, and O. Scheiner. 1993. Four recombinant 

isoforms of Cor a I, the major allergen of hazel pollen. Europ. J. Biochem.

212:355-362.

54. Ipsen, H., and B.C. Hansen. 1991. The NH2-terminal amino acid sequence
of the immunochemically partial identical major allergens of alder (Alnus 

glutinosa) Aln g I, birch (Betula verrucosa) Bet v I, hornbeam (Carpinus betulus) 

Car b I and oak (Quercus alba) Que a I pollens.

Mol. Immunol. 28:1279-1288.

55. Taniai, M., S. Ando, M. Usui, M. Kurimoto, M. Sakaguchi, S. Inouye, and
T. Matuhasi. 1988. N-terminal amino acid sequence of a major allergen of 

Japanese cedar pollen (Cry j I). FEBS Lett. 239:329-332.

56. Griffith, I.J., A. Lussier, R. Garman, R. Koury, H. Yeung, and J. Pollock.

1993. The cDNA cloning of Weep j I, the major allergen of Cryptomeria japonica 

(Japanese cedar) (abst). J. Allergy Clin. Immunol. 91:339.

57. Sakaguchi, M., S. Inouye, M. Taniai, S. Ando, M. Usui, and T. Matuhasi.
1990. Identification of the second major allergen of Japanese cedar pollen.

Allergy 45:309-312.

58. Griffith, I. Personal communication; Immulogic Pharmaceutical Corp.

59. Cardaba, B., D. Hernandez, E. Martin, B. de Andres, V. del Pozo, S.

Gallardo, J.C. Fernandez, R. Rodriguez, M. Villalba, P. Palomino, A. Basomba, 

and C. Lahoz. 1993. Antibody response to olive pollen antigens: association between
HLA class II genes and IgE response to Ole e I (abst). J. Allergy Clin. Immunol
. 91:338.

60. Villalba, M., E. Batanero, C. Lopez-Otin, L.M. Sanchez, R.I. Monsalve, M
.A.

Gonzalez de la Pena, C. Lahoz, and R. Rodriguez. 1993. Amino acid sequence
of Ole e I, the major allergen from olive tree pollen (Olea europaea). Eur.
J. Biochem. 216:863-869.

61. Chua, K. Y., G. A. Stewart, and W. R. Thomas. 1988. Sequence analysis
of cDNA encoding for a major home dust mite allergen, Der p I. J. Exp. Med.

167:175-182.

62. Chua, K. Y., C. R. Doyle, R. J. Simpson, K. J. Turner, G. A. Stewart, and 

W. R. Thomas. 1990. Isolation of cDNA coding for the major mite allergen Der
p II by IgE plaque immunoassay.

Int. Arch. Allergy Appl. Immunol. 91:118-123.

63. Stewart, G.A., L.D. Ward, R.J. Simpson, and P.J. Thompson. 1992. The 

group III allergen from the home dust mite Dermatophagoides pteronyssinus is 

a trypsin-like enzyme. Immunol. 75:29-35.

64. Lake, F.R., L.D. Ward, R.J. Simpson, P.J. Thompson, and G.A. Stewart.

1991. Home dust mite-derived amylase: Allergenicity and physicochemical 

characterisation. J. Allergy Clin. Immunol. 87:1035-1042.

65. Tovey, E.

R., M. C. Johnson, A. L. Roche, G. S. Cobon, and B. A. Baldo.
1989. Cloning and sequencing of a cDNA expressing a recombinant home dust mite
protein that binds human IgE and corresponds to an significant low molecular weight 

allergen. J. Exp. Med. 170:1457-1462.

66. Yasueda, H., T. Shida, T. Ando, S. Sugiyama, and H. Yamakawa. 1991.

Allergenic and proteolytic properties of fourth allergens from Dermatophagoides 

mites. In: «Dust Mite Allergens and Asthma. Report of the 2nd international work

shop» A.

Todt, Ed., UCB Institute of Allergy, Brussels, Belgium, pp. 63-64.

67. Shen, H.-D., K.-Y. Chua, K.-L. Lin, K.-H. Hsieh, and W.R. Thomas. 1993.
Molecular cloning of a home dust mite allergen with common antibody binding 

specificities with multiple components in mite extracts. Clin. Exp. Allergy 23:934-40.

68. Lind, P., O.C. Hansen, and N. Horn. 1988. The binding of mouse hybridoma 

and human IgE antibodies to the major fecal allergen, Der p I of D.

pteronyssinus.

J. Immunol.

What is aspergillus fumigatus allergy

140:4256-4262.

69. Dilworth, R. J., K. Y. Chua, and W. R. Thomas. 1991. Sequence analysis
of cDNA coding for a mojor home dust allergn Der f I. Clin. Exp. Allergy 

21:25-32.

70. Nishiyama, C., T. Yunki, T. Takai, Y. Okumura, and H. Okudaira. 1993.

Determination of three disulfide bonds in a major home dust mite allergen, Der 

f II. Int. Arch. Allergy Immunol. 101:159-166.

71. Trudinger, M., K. Y. Chua, and W. R. Thomas. 1991. cDNA encoding the 

major dust mite allergen Der f II. Clin. Exp. Allergy 21:33-38.

72. Heymann, P.W., M.D. Chapman, R.C.

Aalberse, J.W. Fox, and T.A.E. Platts-
Mills. 1989. Antigenic and structural analysis of group II allergens (Der f II
and Der p II) from home dust mites (Dermatophagoides spp). J. Allergy Clin.

Immunol. 83:1055-1067.

73. van Hage-Hamsten, M., T. Bergman, E. Johansson, B. Persson, H. Jornvall,
B. Harfast, and S.G.O. Johansson. 1993. N-terminal amino acid sequence of 

major allergen of the mite lepidoglyphus destructor (abst).

J. Allergy Clin.

Immunol. 91:353.

74. de Groot, H., K.G.H. Goei, P. van Swieten, and R.C. Aalberse. 1991.

Affinity purification of a major and a minor allergen from dog extract: Serologic
activity of affiity-purified Can f I and Can f I-depleted extract. J. Allergy Clin.

Immunol. 87:1056-1065.

75. Konieczny, A. Personal communication; Immunologic Pharmaceutical Corp.

76. McDonald, B., M. C. Kuo, J. L. Ohman, and L. J. Rosenwasser. 1988.

A 29 amino acid peptide derived from rat alpha 2 euglobulin triggers murine 

allergen specific human T cells (abst).

J. Allergy Clin. Immunol. 83:251.

77. Clarke, A. J., P. M. Cissold, R. A. Shawi, P. Beattie, and J. Bishop. 1984.

Structure of mouse urinary protein genes: differential splicing configurations in 

the 3′-non-coding region. EMBO J 3:1045-1052.

78. Longbottom, J. L. 1983. Chracterization of allergens from the urines 

of experimental animals. McMillan Press, London, pp. 525-529.

79. Laperche, Y., K. R. Lynch, K. P. Dolans, and P. Feigelsen. 1983. Tissue
-specific control of alpha 2u globulin gene expression: constitutive synthesis in 

submaxillary gland.

Cell 32:453-460.

80. Arruda, L.K., B.J. Mann, and M.D. Chapman. 1992. Selective expression
of a major allergen and cytotoxin, Asp f I in Aspergillus fumigatus. J. Immunol
. 149:3554-3559.

81. Kumar, A., L.V. Reddy, A. Sochanik, and V.P. Kurup. 1993. Isolation 

and characterization of a recombinant heat shock protein of Aspergillus fumigatus.
J. Allergy Clin. Immunol. 91:1024-1030.

82. Teshima, R., H. Ikebuchi, J. Sawada, S. Miyachi, S. Kitani, M. Iwama, M.
Irie, M. Ichinoe, and T. Terao. 1993. Isolation and characterization of a major 

allergenic component (gp55) of Aspergillus fumigatus.

J. Allergy Clin. Immunol.

92:698-706.

83. Shen, H.D., K.B. Choo, H.H. Lee, J.C. Hsieh, and S.H. Han. 1991. The 

40 kd allergen of Candida albicans is an alcohol dehydrogenease: molecular 

cloning and immunological analysis using monoclonal antibodies.

Clin. Exp. Allergy 21:675-681.

84. Matthiesen, F., M. Olsen, and H. Lowenstein. 1992. Purification and 

partial sequence of the major allergen of alternaria alternata, Alt a 1.

J. Allergy Clin. Immunol. 89:241.

85. Curran, I.H.A., N.M.

Young, M. Burton, and H.M. Vijay. 1992.

2017

Sokolova V, Shi Z, Huang S, Du Y, Kopp M, Frede A, Knuschke T, Buer J, Yang D, Wu J, Westendorf AM, Epple M: Delivery of the TLR ligand poly(I:C) to liver cells in vitro and in vivo by calcium phosphate nanoparticles leads to a pronounced immunostimulation. Acta Biomater. 2017;64: 401-410

Van der Meer SB, Knuschke T, Frede A, Schulze N, Westendorf AM, Epple M: Avidin-conjugated calcium phosphate nanoparticles as a modular targeting system for the attachment of biotinylated molecules in vitro and in vivo.

Acta Biomater. 2017;57: 414-425

Stein K, Jenckel A, Brand S, Sigmund A, Kirschning CJ, Kauth M, Heine H: RNA is the key element of the th1-promoting and allergy-protective activation of dendritic cells by the cowshed bacterium lactococcus lactis G121. Allergy. 2017;72 103: 93-93

Rahmel T, Asmussen S, Karlik J, Steinmann J, Adamzik M, Peters J: Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS. BMC Anesthesiol. 2017;17(1): 78

Turki AT, Rashidi-Alavijeh J, Dürig J, Gerken G, Rath PM, Witzke O: Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL).

BMC Infect Dis. 2017;17(1): 797

Korth J, Kukalla J, Rath PM, Dolff S, Krull M, Guberina H, Bienholz A, Wilde B, Becker S, Ross B, Anastasiou OE, Kribben A, Witzke O: Increased resistance of gram-negative urinary pathogens after kidney transplantation. BMC Nephrol. 2017;18(1)

Grosse-Onnebrink J, Stehling F, Tschiedel E, Olivier M, Mellies U, Schmidt R, Buer J, Rath PM, Steinmann J: Bacteraemia and fungaemia in cystic fibrosis patients with febrile pulmonary exacerbation: a prospective observational study. BMC Pulm Med. 2017;17(1): 96

Kehrmann J, Veckollari B, Schmidt D, Schildgen O, Schildgen V, Wagner N, Zeschnigk M, Klein-Hitpass L, Witzke O, Buer J, Steinmann J: The lung microbiome in patients with pneumocystosis.

BMC Pulm Med. 2017;17(1): 170

Grassmé H, Henry B, Ziobro R, Becker KA, Riethmüller J, Gardner A, Seitz AP, Steinmann J, Lang S, Ward C, Schuchman EH, Caldwell CC, Kamler, M, Edwards MJ, Brodlie M, Gulbins E: ?1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial Infections. Cell Host Microbe. 2017;21(6): 707-718.e8

Ma Z, Liu J, Wu W, Zhang E, Zhang X, Li Q, Zelinskyy G, Buer J, Dittmer U, Kirschning CJ, Lu M: The IL-1R/TLR signaling pathway is essential for efficient CD8+ T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol Immunol. 2017;14(12): 997-1008

Becker KA, Li X, Seitz A, Steinmann J, Koch A, Schuchman E, Kamler M, Edwards MJ, Caldwell CC, Gulbins E: Neutrophils Kill Reactive Oxygen Species-Resistant Pseudomonas aeruginosa by Sphingosine.

Cell Physiol Biochem. 2017;43(4): 1603-1616

Westendorf AM, Skibbe K, Adamczyk A, Buer J, Geffers R, Hansen W, Pastille E, Jendrossek V: Hypoxia Enhances Immunosuppression by Inhibiting CD4+ Effector T Cell Function and Promoting Treg Activity. Cell Physiol Biochem. 2017;41(4): 1271-1284

Köhling HL, Plummer SF, Marchesi JR, Davidge KS, Ludgate M: The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. Clin Immunol. 2017;183: 63-74

Gharun K, Senges J, Seidl M, Lösslein A, Kolter J, Lohrmann F, Fliegauf M, Elgizouli M, Vavra M, Schachtrup K, Illert AL, Gilleron M, Kirschning CJ, Triantafyllopoulou A, Henneke P: Mycobacteria exploit nitric oxide-induced transformation of macrophages into permissive giant cells.

EMBO Rep. 2017;18(12): 2144-2159

Barthel R, Buer J, Hansen W: Neuropilin-1 and its role in intratumoral CD4+T cell function: Eur J Immunol. 2017;47 2: 266-266

Pastille E, Frede A, Adamczyk A, McSorley H, Maizels R, Buer J, Westendorf A: Helminth-induced intestinal inflammation facilitates tumor growth and progression in colitis-associated colon cancer. Eur J Immunol. 2017;47 2: 67-67

Schoemer D, Adamczyk A, Pastille E, Westendorf A, Buer J, Kehrmann J: Analysis of the gut microbiome in Foxp3+Regulatory T cell depleted mice. Eur J Immunol. 2017;47 2: 212-212

Makkawi H, Hoch S, Burns E, Hosur K, Hajishengallis G, Kirschning CJ, Nussbaum G: Porphyromonas gingivalis Stimulates TLR2-PI3K Signaling to Escape Immune Clearance and Induce Bone Resorption Independently of MyD88.

Front Cell Infect Microbiol. 2017;7: 359

Loevenich K, Ueffing K, Abel S, Hose M, Matuschewski K, Westendorf AM, Buer J, Hansen W: DC-Derived IL-10 Modulates Pro-inflammatory Cytokine Production and Promotes Induction of CD4+IL-10+ Regulatory T Cells during Plasmodium yoelii Infection. Front Immunol. 2017;8: 152

Smirnov A, Pohlmann S, Nehring M, Ali S, Mann-Nüttel R, Scheu S, Antoni AC, Hansen W, Büettner M, Gardiasch MJ, Westendorf AM, Wirsdörfer F, Pastille E, Dudda M, Flohé SB: Sphingosine 1-Phosphate- and C-C Chemokine Receptor 2-Dependent Activation of CD4+ Plasmacytoid Dendritic Cells in the Bone Marrow Contributes to Signs of Sepsis-Induced Immunosuppression.

Front Immunol. 2017;8: 1622

Ueffing K, Abberger H, Westendorf AM, Matuschewski K, Buer J, Hansen W: Conventional CD11chigh Dendritic Cells Are Significant for T Cell Priming during the Initial Phase of Plasmodium yoelii Infection, but Are Dispensable at Later Time Points. Front Immunol. 2017;8: 1333

Krieg SM, Voigt F, Knuefermann P, Kirschning CJ, Plesnila N, Ringel F: Decreased Secondary Lesion Growth and Attenuated Immune Response after Traumatic Brain Injury in Tlr2/4-/- Mice.

Front Neurol. 2017;8: 455

Parohl N, Stiefenhöfer D, Heiligtag S, Reuter H, Dopadlik D, Mosel F, Gerken G, Dechêne A, Heintschel von Heinegg E, Jochum C, Buer J, Popp W: Monitoring of endoscope reprocessing with an adenosine triphosphate (ATP) bioluminescence method. GMS Hyg Infect Control. 2017;12: Doc04

Wöchtl B, Gunzer F, Gerner W, Gasse H, Koch M, Bagó Z, Ganter M, Weissenböck H, Dinhopl N, Coldewey SM, von Altrock A, Waldmann KH, Saalmüller A, Zimmermann K, Steinmann J, Kehrmann J, Klein-Hitpass L, Blom J, Ehricht R, Engelmann I, Hennig-Pauka I: Comparison of clinical and immunological findings in gnotobiotic piglets infected with Escherichia coli O104:H4 outbreak strain and EHEC O157:H7.

Gut Pathog. 2017;9: 30

Stein K, Brand S, Jenckel A, Sigmund A, Chen ZJ, Kirschning CJ, Kauth M, Heine H: Endosomal recognition of Lactococcus lactis G121 and its RNA by dendritic cells is key to its allergy-protective effects. J Allergy Clin Immunol. 2017;139(2): 667-678.e5

Koroska F, Göttig S, Kaase M, Steinmann J, Gatermann S, Sommer J, Wille T, Plum G, Hamprecht A: Comparison of Phenotypic Tests and an Immunochromatographic Assay and Development of a New Algorithm for Detection of OXA-48-like Carbapenemases.

J Clin Microbiol. 2017;55(3): 877-883

Siddharta A, Pfaender S, Vielle NJ, Dijkman R, Friesland M, Becker B, Yang J, Engelmann M, Todt D, Windisch MP, Brill FH, Steinmann J, Steinmann J, Becker S, Alves MP, Pietschmann T, Eickmann M, Thiel V, Steinmann E: Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. J Infect Dis. 2017;215(6): 902-906

Adamczyk A, Gageik D, Frede A, Pastille E, Hansen W, Rueffer A, Buer J, Buning J, Langhorst J, Westendorf AM: Differential expression of GPR15 on T cells during ulcerative colitis: Journal of clinical investigation insight.

2017;2(8): e90585

Jager M, Jennissen HP, Dittrich F, Fischer A, Kohling HL: Antimicrobial and Osseointegration Properties of Nanostructured Titanium Orthopaedic Implants. Materials (Basel). 2017;10(11): 1302

Spettel K, Barousch W, Makristathis A, Hirschl A, Nehr M, Selitsch B, Lackner M, Rath PM, Steinmann J, Willinger B: Analysis of resistance genes in Candida albicans and Candida glabrata using Next Generation Sequencing: Mycoses. 2017;60 1: 15-15

Steinmann J, Radke J, Schmidt D, Rath PM: Development of a highly discriminatory multilocus microsatellite typing method for Cunninghamella bertholletiae. Mycoses. 2017;60 2: 202-202

Steinmann J, Brill F: In vitro Efficacy of Disinfectants against clinically relevant Fungi.

Mycoses. 2017;60 1: 26-27

Frede A, Neuhaus B, Knuschke T, Wadwa M, Kollenda S, Klopfleisch R, Hansen W, Buer J, Bruder D, Epple M, Westendorf AM: Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation. Nanomedicine. 2017;13(8): 2395-2403

Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S: Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun. 2017;8: 14600

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Genuine B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein- Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A: Acquired IFN?

resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8: 15440

Boch T, Spiess B, Liebregts T, Schellongowski P, Meybohm P, Rath PM, Steinmann J, Britsch S, Michels J, Jabbour C, Hofmann WK, Reinwald M, Buchheidt D: Detection of invasive pulmonary aspergillosis in criticially ill patients with mechanical ventilation by combined use of conventional culture, galactomannan, 1-3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction.

Oncology Research and treatment. 2017;40 3: 223-223

Spiess B, Skladny J, Postina P, Boch T, Rath PM, Steinmann J, Cornely OA, Miethke T, Dietz A, Merker N, Hofmann WK, Buchheidt D: Detection of Aspergillus DNA and azole resistance mutations from BAL samples of immunocompromised patients and from serially diluted Aspergillus fumigatus conidia in BAL fluid sensitivity comparison of two molecular assays. Oncology Research and treatment. 2017;40 3: 223-223

Saeedghalati M, Farahpour F, Budeus B, Lange A, Westendorf AM, Seifert M, Küppers R, Hoffmann D: Quantitative Comparison of Abundance Structures of Generalized Communities: From B-Cell Receptor Repertoires to Microbiomes.

PLoS Comput Biol. 2017;13(1): e1005362

Pastille E, Frede A, McSorley HJ, Gräb J, Adamczyk A, Kollenda S, Hansen W, Epple M, Buer J, Maizels RM, Klopfleisch R, Westendorf AM: Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer. PLoS Pathog. 2017;13(9)

Stehling F, Steinmann J, Mellies U: The microbiome and secondary lung disease in neuromuscular patients: Is it time to change our clinical practice? — Reply. Respirology. 2017;22(5): 1036

Kirchhoff L, Olsowski M, Zilmans K, Dittmer S, Haase G, Sedlacek L, Steinmann E, Buer J, Rath PM, Steinmann J: Biofilm formation of the black yeast-like fungus Exophiala dermatitidis and its susceptibility to antiinfective agents.

Sci Rep. 2017;7: 42886

Stock AK, Dajkic D, Köhling HL, von Heinegg EH, Fiedler M, Beste C: Humans with latent toxoplasmosis display altered reward modulation of cognitive control. Sci Rep. 2017;7(1): 10170

Braunwarth H, Brill FH, Steinmann J, Hegeholz D, Droste W: [Migration speed of uropathogens : Determination in the ureteral splint in a practice-like in vitro model]. Urologe A. 2017;56(2): 180-185

Pastille E, Frede A, McSorley HJ, Gräb J, Adamczyk A, Kollenda S, Hansen W, Epple M, Buer J, Maizels RM, Klopfleisch R, Westendor PLoS Pathog.

2017;13(9): e1006649 f AM: Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer.

Stehling F, Steinmann J, Mellies U. The microbiome and secondary lung disease in neuromuscular patients: Is it time to change our clinical practice? — Reply. Respirology. 2017;22(5): 1036 (Impact(2016)=3.256, Typ=Letter)

Kirchhoff L, Olsowski M, Zilmans K, Dittmer S, Haase G, Sedlacek L, Steinmann E, Buer J, Rath PM, Steinmann J: Biofilm formation of the black yeast-like fungus Exophiala dermatitidis and its susceptibility to antiinfective agents. Sci Rep.

2017;7: 42886

Stock AK, Dajkic D, Köhling HL, von Heinegg EH, Fiedler M, Beste C: Humans with latent toxoplasmosis display altered reward modulation of cognitive control. Sci Rep. 2017;7(1): 10170

Braunwart H, Brill FH, Steinmann J, Hegenholz D, Droste W: Migration speed of uropathogens : Determination in the ureteral splint in a practice-like in vitro model. Urologe A. 2017;56(2): 180-185

2016

Wadwa M, Klopfleisch R, Buer J, Westendorf AM: Targeting antigens to DEC-205 on dendritic cells induces immune protection in experimental colitis in mice.

European Journal of Microbiology and Immunology 2016, 6(1):1-8.

Wadwa M, Klopfleisch R, Adamczyk A, Frede A, Pastille E, Mahnke K, Hansen W, Geffers R, Lang KS, Buer J, Buning J, Westendorf AM: IL-10 downregulates CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites. Mucosal Immunol 2016.

Troger B, Hartel C, Buer J, Dordelmann M, Felderhoff-Muser U, Hohn T, Hepping N, Hillebrand G, Kribs A, Marissen J, Olbertz D, Rath PM, Schmidtke S, Siegel J, Herting E, Gopel W, Steinmann J, Stein A: Clinical Relevance of Pathogens Detected by Multiplex PCR in Blood of Very-Low-Birth Weight Infants with Suspected Sepsis — Multicentre Study of the German Neonatal Network.

PLoS One 2016, 11(7):e0159821.

Steinmann J, Dittmer S, Houbraken J, Buer J, Rath PM: In vitro activity of isavuconazole against Rasamsonia species. Antimicrob Agents Chemother 2016.

Steinmann J, Buer J, Rath PM: Detection of Aspergillus fumigatus in Blood Samples from Critically Ill Patients in Intensive Care Units by Use of the SeptiFast Assay. J Clin Microbiol 2016, 54(7):1918-1921.

Serdar M, Herz J, Kempe K, Lumpe K, Reinboth BS, Sizonenko SV, Hou X, Herrmann R, Hadamitzky M, Heumann R, Hansen W, Sifringer M, van de Looij Y, Felderhoff-Muser U, Bendix I: Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia.

Brain Behav Immun 2016, 52:106-119.

Knuschke T, Rotan O, Bayer W, Sokolova V, Hansen W, Sparwasser T, Dittmer U, Epple M, Buer J, Westendorf AM: Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. Retrovirology 2016, 13(1):24.

Klotz U, Schmidt D, Willinger B, Steinmann E, Buer J, Rath PM, Steinmann J: Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria. Mycoses 2016.

Kehrmann J, Wessel S, Murali R, Hampel A, Bange FC, Buer J, Mosel F: Principal component analysis of MALDI TOF MS mass spectra separates M.

abscessus (sensu stricto) from M. massiliense isolates. BMC Microbiol 2016, 16(1):24.

Kehrmann J, Schoerding AK, Murali R, Wessel S, Koehling HL, Mosel F, Buer J: Performance of Vitek MS in identifying nontuberculous mycobacteria from MGIT liquid medium and Lowenstein-Jensen solid medium. Diagn Microbiol Infect Dis 2016, 84(1):43-47.

Kehrmann J, Kurt N, Rueger K, Bange FC, Buer J: GenoType NTM-DR for identifying Mycobacterium abscessus subspecies and determining molecular resistance.

J Clin Microbiol 2016.

Gamrad L, Rehbock C, Westendorf AM, Buer J, Barcikowski S, Hansen W: Efficient nucleic acid delivery to murine regulatory T cells by gold nanoparticle conjugates. Sci Rep 2016, 6:28709.

Frede A, Neuhaus B, Klopfleisch R, Walker C, Buer J, Muller W, Epple M, Westendorf AM: Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. J Control Release 2016, 222:86-96.

Berchner-Pfannschmidt U, Moshkelgosha S, Diaz-Cano S, Edelmann B, Gortz GE, Horstmann M, Noble A, Hansen W, Eckstein A, Banga JP: Comparative assessment of female mouse model of Graves’ orbitopathy under diverse environments, accompanied by pro-inflammatory cytokine and T cell responses to thyrotropin hormone receptor antigen.

Endocrinology 2016:en20151829.

Abel S, Ueffing K, Tatura R, Hutzler M, Hose M, Matuschewski K, Kehrmann J, Westendorf AM, Buer J, Hansen W: Plasmodium yoelii infection of BALB/c mice results in expansion rather than induction of CD4 Foxp3 regulatory T cells. Immunology 2016.

2015

Tatura R, Zeschnigk M, Hansen W, Steinmann J, Vidigal PG, Hutzler M, Pastille E, Westendorf AM, Buer J, Kehrmann J: Relevance of Foxp3(+) regulatory T cells for early and tardy phases of murine sepsis.

Immunology 2015, 146(1):144-156.

Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM: Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015, 70(5):1522-1526.

Sokolova V, Westendorf AM, Buer J, Überla K, Epple M: The potential of nanoparticles for the immunization against viral infections. J Mater Chem B 2015, 3(24):4767-4779.

Seiffart V, Zoeller J, Klopfleisch R, Wadwa M, Hansen W, Buer J, Riedel C, Westendorf AM: IL10-Deficiency in CD4(+) T Cells Exacerbates the IFNgamma and IL17 Response During Bacteria Induced Colitis.

Cell Physiol Biochem 2015, 36(4):1259-1273.

Rath PM, Schoch B, Adamzik M, Steinmann E, Buer J, Steinmann J: Reply: PCR assay for pathogen detection in ventriculostomy-related meningitis in neurosurgery patients: unanswered questions? Infection 2015, 43(2):251-252.

Popp W, Mosel, F., Parohl, N., Monats, M., Ross, B., Buer, J.: Multiresistente gramnegative Erreger in Spülrändern von Krankenhaustoiletten. Hyg Med 2015, 9:40-49.

Niezold T, Storcksdieck Genannt Bonsmann M, Maaske A, Temchura V, Heinecke V, Hannaman D, Buer J, Ehrhardt C, Hansen W, Uberla K, Tenbusch M: DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?

Immunology 2015, 145(4):519-533.

Kruger A, Oldenburg M, Chebrolu C, Beisser D, Kolter J, Sigmund AM, Steinmann J, Schafer S, Hochrein H, Rahmann S, Wagner H, Henneke P, Hornung V, Buer J, Kirschning CJ: Human TLR8 senses UR/URR motifs in bacterial and mitochondrial RNA. Embo Rep 2015.

Koehling HL, Willinger B, Buer J, Rath PM, Steinmann J: Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates. J Clin Microbiol 2015, 53(1):255-261.

Khairnar V, Duhan V, Maney SK, Honke N, Shaabani N, Pandyra AA, Seifert M, Pozdeev V, Xu HC, Sharma P, Baldin F, Marquardsen F, Merches K, Lang E, Kirschning C, Westendorf AM, Haussinger D, Lang F, Dittmer U, Kuppers R, Recher M, Hardt C, Scheffrahn I, Beauchemin N, Gothert JR, Singer BB, Lang PA, Lang KS: CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production.

Nat Commun 2015, 6:6217.

Kehrmann J, Schoerding AK, Murali R, Wessel S, Koehling HL, Mosel F, Buer J: Performance of Vitek MS in identifying nontuberculous mycobacteria from MGIT liquid medium and Lowenstein-Jensen solid medium. Diagn Microbiol Infect Dis 2015.

Henry BD, Neill DR, Becker KA, Gore S, Bricio-Moreno L, Ziobro R, Edwards MJ, Muhlemann K, Steinmann J, Kleuser B, Japtok L, Luginbuhl M, Wolfmeier H, Scherag A, Gulbins E, Kadioglu A, Draeger A, Babiychuk EB: Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol 2015, 33(1):81-88.

Chebrolu C, Artner D, Sigmund AM, Buer J, Zamyatina A, Kirschning CJ: Species and mediator specific TLR4 antagonism in primary human and murine immune cells by betaGlcN(1<—>1)alphaGlc based lipid A mimetics.

Mol Immunol 2015, 67(2 Pt B):636-641.

2014

Vidigal PG, Musken M, Becker KA, Haussler S, Wingender J, Steinmann E, Kehrmann J, Gulbins E, Buer J, Rath PM, Steinmann J: Effects of Green Tea Compound Epigallocatechin-3-Gallate against Stenotrophomonas maltophilia Infection and Biofilm. Plos One 2014, 9(4).

Vidigal PG, Mosel F, Koehling HL, Mueller KD, Buer J, Rath PM, Steinmann J: Delineation of Stenotrophomonas maltophilia isolates from cystic fibrosis patients by fatty acid methyl ester profiles and matrix-assisted laser desorption/ionization time-of-flight mass spectra using hierarchical cluster analysis and principal component analysis.

J Med Microbiol 2014, 63:1615-1620.

Vidigal PG, Dittmer S, Steinmann E, Buer J, Rath PM, Steinmann J: Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: Molecular diversity, mutation frequency and antibiotic resistance. Int J Med Microbiol 2014, 304(5-6):613-619.

Ross B, Steinmann J, Buer J, Dusse F, Jakob H, Schneemann H, Hugo-Hanke S, Brautigam S, Sanewski A, Kundt R, Parohl N, Weidler K, Witzke O, Popp W: Outbreak with Ralstonia pickettii caused by contaminated magnesium vials. Deut Med Wochenschr 2014, 139(7):323-326.

Rath PM, Schoch B, Adamzik M, Steinmann E, Buer J, Steinmann J: Worth of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients.

Infection 2014, 42(4):621-627.

Pastille E, Bardini K, Fleissner D, Adamczyk A, Frede A, Wadwa M, von Smolinski D, Kasper S, Sparwasser T, Gruber AD, Schuler M, Sakaguchi S, Roers A, Muller W, Hansen W, Buer J, Westendorf AM: Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer. Cancer Research 2014, 74(16):4258-4269.

Langhorst J, Frede A, Knott M, Pastille E, Buer J, Dobos GJ, Westendorf AM: Distinct Kinetics in the Frequency of Peripheral CD4(+) T Cells in Patients with Ulcerative Colitis Experiencing a Flare during Treatment with Mesalazine or with a Herbal Preparation of Myrrh, Chamomile, and Coffee Charcoal.

Plos One 2014, 9(8).

Knuschke T, Bayer W, Rotan O, Sokolova V, Wadwa M, Kirschning CJ, Hansen W, Dittmer U, Epple M, Buer J, Westendorf AM: Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection. Nanomed-Nanotechnol 2014, 10(8):1787-1798.

Kehrmann J, Tatura R, Zeschnigk M, Probst-Kepper M, Geffers R, Steinmann J, Buer J: Impact of 5-aza-2-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. Immunology 2014, 142(3):384-395.

Jost NH, Abel S, Hutzler M, Sparwasser T, Zimmermann A, Roers A, Muller W, Klopfleisch R, Hengel H, Westendorf AM, Buer J, Hansen W: Regulatory T cells and T-cell-derived IL-10 interfere with effective anti-cytomegalovirus immune response.

Immunol Cell Biol 2014, 92(10):860-871.

Jockenhofer F, Gollnick H, Herberger K, Isbary G, Renner R, Stucker M, Valesky E, Wollina U, Weichenthal M, Karrer S, Ross B, Heintschel von Heinegg E, Dissemond J: Current detection rates of multiresistant gram negative bacteria (3MRGN, 4MRGN) in patients with chronic leg ulcers. Hautarzt 2014, 65(11):967-973.

Jockenhofer F, Chapot V, Stoffels-Weindorf M, Korber A, Klode J, Buer J, Kupper B, Roesch A, Dissemond J: Bacterial spectrum colonizing chronic leg ulcers: A 10-year comparison from a German wound care middle.

J Dtsch Dermatol Ges 2014, 12(12):1121-1127.

Herz J, Hagen SI, Bergmuller E, Sabellek P, Gothert JR, Buer J, Hansen W, Hermann DM, Doeppner TR: Exacerbation of ischemic brain injury in hypercholesterolemic mice is associated with pronounced changes in peripheral and cerebral immune responses. Neurobiol Dis 2014, 62:456-468.

Al Ghazal P, Korber A, Klode J, Schmid EN, Buer J, Dissemond J: Evaluation of the Essen Rotary as a new technique for bacterial swabs: results of a prospective controlled clinical investigation in 50 patients with chronic leg ulcers.

Int Wound J 2014, 11(1):44-49.

Jockenhöfer, F., V. Chapot, M. Stoffels-Weindorf, A. Körber, J. Buer, B. Kuepper, A. Roesch, J. Dissemond. Bakterielles Spektrum der Kolonisation des chronischen Ulcus cruries: 10-Jahres-Verleichsstudie eines deutschen Wundbehandlunsgzentrums. J Dtsch Dermatol Ges. 2014 Dec; 12(12):1121-8

Jockenhofer., F., V. Chapot, M. Stoffels-Weindorf, A. Korber, J. Klode, J. Buer, B. Kupper, A. Roesch, J. Dissemond J. Bacterial spectrum colonizing chronic leg ulcers: A 10-year comparison from a German wound care middle. J Dtsch Dermatol Ges 2014 December;12(12):1121-7.

Koehling, H.L., B. Willinger, J.

Buer, P.M. Rath, J. Steinmann. Comparative Evaluation of a New Commercial Colorimetric Microdilution Assay (SensiQuattro Candida EU) with MIC Test Strip and EUCAST Broth Microdilution Methods for Susceptibility Testing of Invasive Candida Isolates. J Clin Microbiol 2015 January;53(1):255-61.

Steinmann, J., S. Giraud, D. Schmidt, L. Sedlacek, A. Hamprecht, J. Houbraken, J.F. Meis, J.P. Bouchara, J. Buer, P.M. Rath.

Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complicated in respiratory secretions from cystic fibrosis patients. New Microbes New Infect 2014 May;2(3):72-8.

Vidigal., P.G., F. Mosel, H.L. Koehling, K.D. Mueller, J. Buer, P.M. Rath, J. Steinmann. Delineation of Stenotrophomonas maltophilia isolates from cystic fibrosis patients by fatty acid methyl ester profiles and matrix-assisted laser desorption/ionization time-of-flight mass spectra using hierarchical cluster analysis and principal component analysis.

J Med Microbiol 2014 December;63(Pt 12):1615-20.

Langhorst., J, A. Frede, M. Knott, E. Pastille, J. Buer, G.J. Dobos, A.M. Westendorf. Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal. PLoS One 2014;9(8):e104257.

Jost, N.H., S. Abel, M. Hutzler, T. Sparwasser, A. Zimmermann, A. Roers, W. Müller, R. Kopfleisch, H. Hengel, A.M. Westendorf, J. Buer, W. Hansen.

Regulatory T cells and T-cell-derived IL-10 interfere with effective anti-cytomegalovirus immune response. Immunology and Cell Biology. 29 Juli 2014; doi: 1038/icb.2014.62 (Epub ahead of print)

Knuschke, T., W. Bayer, O. Rotan, V. Sokolova, M. Wadwa, CJ. Kirschning, W. Hansen, U. Dittmer, M. Epple, J. Buer, AM. Westendorf. Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protecitve immunity during acute and chronic retroviral infection.

Nanomedicine. 2014 Jul 8. pii: S1549-9634(14)00327-X.

Pastille, E., K. Bardini, D. Fleissner, A. Adamczyk, A. Frede, M. Wadwa, D. von Smolinski, S. Kasper, T. Sparwasser, A.D. Gruber, M. Schuler, S. Sakaguchi, A. Roers, W. Müller, W. Hansen, J. Buer , A.M. Westendorf. Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res. 2014 Aug 15;74(16):4258-69.

Vidigal, P.G., S. Dittmer, E. Steinmann, J. Buer, P.M. Rath, J. Steinmann. Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. Int J Med Microbiol. 2014 Jul;304(5-6):613-9.

Vidigal, P.G., M. Müsken, K.A. Becker, S. Häussler, J. Wingender, E. Steinmann, J. Kehrmann, E. Gulbins, J. Buer, P.M. Rath, J. Steinmann. Effects of green tea compound epigallocatechin-3-gallate against Stenotrophomonas maltophilia infection and biofilm. PLoS One. 2014 Apr 1;9(4):e92876.

Ross, B., J. Steinmann, J. Buer, F. Dusse, H. Jakob, H. Schneemann, S. Hugo-Hanke, S. Bräutigam, A. Sanewski, R. Kundt, N. Parohl, K. Weidler, O. Witzke, W. Popp. Outbreak with Ralstonia pickettii caused by contaminated magnesium vials.

Dtsch Med Wochenschr. 2014 Feb;139(7):323-6.

Kehrmann, J., R. Tatura, M. Zeschnigk, M. Probst-Kepper, R. Geffers, J. Steinmann, J. Buer. Impact of 5-aza-2′-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. Immunology. 2014 Jul;142(3):384-95.

Rath, P.M., B. Schoch, M. Adamzik, E. Steinmann, J. Buer , J. Steinmann. Worth of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients. Infection. 2014 Aug;42(4):621-7.

Kozlova, D., V. Sokolova, M. Zhong, E. Zhang, J. Yang, W. Li, Y. Yang, J. Buer, A.M.

Westendorf, M. Epple, H. Yan. Calcium phopshate nanoparticles show an effective activation of the innate immune response in vitro and in vivo after functionalization with flagellin. Virol Sin. 2014 Feb;29(1):33-9.

Herz, J., S.I. Hagen, E. Bergmüller, P. Sabellek, J.R. Göthert, J. Buer, W. Hansen, D.M. Hermann, T.R. Doeppner. Exacerbation of ischemic brain injury in hypercholesterolemic mice is associated with pronounced changes in peripheral and cerebral immune responses.

Neurobiol Dis. 2014 Feb;62:456-68.

Al Ghazal, P., A. Körber, J. Klode, E.N. Schmid, J. Buer, J. Dissemond. Evaluation of the Essen Rotary as a new technique for bacterial swabs: results of a prospective controlled clinical investigation in 50 patients with chronic leg ulcers. Int Wound J. 2014 Feb;11(1):44-9.

2013

Schemuth H, Dittmer S, Lackner M, Sedlacek L, Hamprecht A, Steinmann E, buer J, Rath PM, Steinmann J: In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis.

Mycoses 2013, 56 (3):297-303

Goncalves, V.P., D. Schmidt, F. Stehling, U. Mellies, E. Steinmann, J. Buer, P.M. Rath, J. Steinmann. Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis. J Cyst Fibros 2013 December;12(6):651-4.

Knuschke, T., V. Sokolova, O. Rotan, M. Wadwa, M. Tenbusch, W. Hansen, P. Staeheli, M. Epple, J. Buer, A.M. Westendorf. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection.

J Immunol 2013 June 15;190(12):6221-9.

Sokolova, V., D. Kozlova, T. Knuschke, J. Buer, A. M. Westendorf, and M. Epple. 2013. Mechanism of the uptake of cationic and anionic calcium phosphate nanoparticles by cells. Acta Biomater. July;9(7):7527-35.

Steinmann, J., J. Buer, T. Pietschmann, and E. Steinmann. 2013. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. 168: 1059-1073.

2012

Abel, S., N. Luckheide, A. M. Westendorf, R. Geffers, A. Roers, W. Muller, T. Sparwasser, K. Matuschewski, J. Buer, and W.

Hansen. 2012. Strong Impact of CD4+Foxp3+ Regulatory T Cells and Limited Effect of T Cell-Derived IL-10 on Pathogen Clearance during Plasmodium yoelii Infection. J. Immunol. 188: 5467-5477.

Al, G. P., A. Korber, J. Klode, E. N. Schmid, J. Buer, and J. Dissemond. 2012. Evaluation of the Essen Rotary as a new technique for bacterial swabs: results of a prospective controlled clinical investigation in 50 patients with chronic leg ulcers. Int. Wound. J.

Hansen, W., M. Hutzler, S. Abel, C. Alter, C. Stockmann, S. Kliche, J. Albert, T. Sparwasser, S. Sakaguchi, A. M. Westendorf, D. Schadendorf, J. Buer, and I. Helfrich. 2012. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.

J. Exp. Med. 209: 2001-2016.

Heintschel von, H. E., J. Steinmann, J. Buer, and P. M. Rath. 2012. Infektionen durch Pilze. In Labor und Diagnose , 8 ed. L. Thomas, ed. TH-Books, Frankfurt/Main. 2127-2143.

Jeron, A., W. Hansen, F. Ewert, J. Buer, R. Geffers, and D. Bruder. 2012. ChIP-on-chip analysis identifies IL-22 as direct target gene of ectopically expressed FOXP3 transcription factor in human T cells. BMC. Genomics 13: 705.

Kohling, H. L., A. Bittner, K. D. Muller, J. Buer, M. Becker, H. Rubben, A. W. Rettenmeier, and F. Mosel. 2012. Direkte Identifizierung von Bakterien im Urin mittels MALDI-TOF-MS.

Mikrobiologe 22: 97-104.

Kohling, H. L., A. Bittner, K. D. Muller, J. Buer, M. Becker, H. Rubben, A. W. Rettenmeier, and F. Mosel. 2012. Direct identification of bacteria in urine samples by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and relevance of defensins as interfering factors. J. Med. Microbiol. 61: 339-344.

Kozlova, D., S. Chernousova, T. Knuschke, J. Buer, A. M. Westendorf, and M. Epple. 2012. Cell targeting by antibody-functionalized calcium phosphate nanoparticles. Journal of Materials Chemistry 22: 396-404.

Metz, C. H., J. Buer, N. Bornfeld, and A. Lipski. 2012. Bilateral Bartonella henselae neuroretinitis with stellate maculopathy in a 6-year-old boy.

Infection 40: 191-194.

Oldenburg, M., A. Kruger, R. Ferstl, A. Kaufmann, G. Nees, A. Sigmund, B. Bathke, H. Lauterbach, M. Suter, S. Dreher, U. Koedel, S. Akira, T. Kawai, J. Buer, H. Wagner, S. Bauer, H. Hochrein, and C. J. Kirschning. 2012. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 337: 1111-1115.

Rath, P. M., D. Buchheidt, B.

Spiess, E. Arfanis, J. Buer, and J. Steinmann. 2012. First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob. Agents Chemother. 56: 6060-6061.

Rath, P. M., F. Saner, A. Paul, N. Lehmann, E. Steinmann, J. Buer, and J. Steinmann. 2012. Multiplex PCR for rapid and improved diagnosis of bloodstream infections in liver transplant recipients. J. Clin. Microbiol. 50: 2069-2071.

Riss, G. L., D. I. Chang, C. Wevers, A. M. Westendorf, J. Buer, N. Scherbaum, and W. Hansen. 2012. Opioid maintenance therapy restores CD4(+) T cell function by normalizing CD4(+)CD25(high) regulatory T cell frequencies in heroin user.

Brain Behav. Immun. 26: 972-978.

Ross, B., O. Witzke, A. Kribben, H. E. Heintschel von, J. Buer, G. Gerken, M. Fiedler, and W. Popp. 2012. Managing EHEC in hospital routine. Dtsch. Med. Wochenschr. 137: 933-936.

Schemuth, H., S. Dittmer, M. Lackner, L. Sedlacek, A. Hamprecht, E. Steinmann, J. Buer, P. M. Rath, and J. Steinmann. 2012. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses.

Sokolova, V., O. Rotan, J. Klesing, P. Nalbant, J. Buer, T. Knuschke, A. M. Westendorf, and M. Epple. 2012. Calcium phosphate nanoparticles as versatile carrier for little and large molecules across cell membranes.

Journal of Nanoparticle Research 14.

Tatura, R., M. Zeschnigk, M. Adamzik, M. Probst-Kepper, J. Buer, and J. Kehrmann. 2012. Quantification of regulatory T cells in septic patients by real-time PCR-based methylation assay and flow cytometry. PLoS. ONE. 7: e49962.

Tosiek, M. J., S. R. Bader, A. D. Gruber, J. Buer, M. Gereke, and D. Bruder. 2012. CD8(+) T cells responding to alveolar self-antigen lack CD25 expression and fail to precipitate autoimmunity. Am. J. Respir. Cell Mol. Biol. 47: 869-878.

Tschiedel, E., J. Steinmann, J. Buer, J. G. Onnebrink, U. Felderhoff-Muser, P.

M. Rath, and C. Dohna-Schwake. 2012. Results and relevance of molecular detection of pathogens by SeptiFast—a retrospective analysis in 75 critically ill children. Klin. Padiatr. 224: 12-16.

2011

Fleissner, D., A. Frede, M. Knott, T. Knuschke, R. Geffers, W. Hansen, G. Dobos, J. Langhorst, J. Buer, and A. M. Westendorf. 2011. Generation and function of immunosuppressive human and murine CD8+ T cells by transforming growth factor-beta and retinoic acid. Immunology 134: 82-92.

Fleissner, D., K. Loser, W. Hansen, J. Dissemond, A. Körber, S. Beissert, J.

Buer, and A. M. Westendorf. 2011. In vitro induced CD8+ regulatory T cells inhibit skin inflammation. European Journal of Microbiology and Immunology 1: 208-214.

Goncalves-Vidigal, P., J. Grosse-Onnebrink, U. Mellies, J.

What is aspergillus fumigatus allergy

Buer, P. M. Rath, and J. Steinmann. 2011. Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance. J. Cyst. Fibros. 10: 422-427.

Kehrmann, J., M. Zeschnigk, J. Buer, and M. Probst-Kepper. 2011. FOXP3 expression in GARP-transduced helper T cells is not associated with FOXP3 TSDR demethylation. Transfusion Medicine and Hemotherapy 38: 287-291.

Kehrmann, J., M.

Kaase, F. Szabados, S. G. Gatermann, J. Buer, P. M. Rath, and J. Steinmann. 2011. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur. J. Clin. Microbiol. Infect. Dis. 30: 677-683.

Lipski, A., J. Buer, N. Bornfeld, and C. H. Metz. 2011. Katzenkratzkrankheit — ein dicker Floh im Heuhaufen? Zeitschrift für praktische Augenheilkunde 32: 409-412.

Schenk, U., M. Frascoli, M.

Proietti, R. Geffers, E. Traggiai, J. Buer, C. Ricordi, A. M. Westendorf, and F. Grassi. 2011. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci. Signal. 4: ra12.

Sokolova, V., T. Knuschke, J. Buer, A. M. Westendorf, and M. Epple. 2011. Quantitative determination of the composition of multi-shell calcium phosphate-oligonucleotide nanoparticles and their application for the activation of dendritic cells. Acta Biomater. 7: 4029-4036.

Steinmann, J., J. Huelsewede, J.

Buer, and P. M. Rath. 2011. Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. Mycoses 54: e421-e428.

Steinmann, J., D. Schmidt, J. Buer, and P. M. Rath. 2011. Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequence-based PCR. Med. Mycol. 49: 475-483.

Steinmann, J., M. Kaase, S. Gatermann, W. Popp, E. Steinmann, M.

Damman, A. Paul, F. Saner, J. Buer, and P. Rath. 2011. Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro. Surveill 16: 19944.

Tosiek, M. J., A. D. Gruber, S. R. Bader, S. Mauel, H. G. Hoymann, S. Prettin, T. Tschernig, J. Buer, M. Gereke, and D. Bruder. 2011. CD4+CD25+Foxp3+ regulatory T cells are dispensable for controlling CD8+ T cell-mediated lung inflammation. J. Immunol. 186: 6106-6118.

2010

Bar-On, L., T.

Birnberg, K. L. Lewis, B. T. Edelson, D. Bruder, K. Hildner, J. Buer, K. M. Murphy, B. Reizis, and S. Jung. 2010. CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U. S. A 107: 14745-14750.

Fleissner, D., W. Hansen, R. Geffers, J. Buer, and A. M. Westendorf. 2010. Local induction of immunosuppressive CD8+ T cells in the gut-associated lymphoid tissues. PLoS. ONE. 5: e15373.

Hansen, W., A.

M. Westendorf, T. Toepfer, S. Mauel, R. Geffers, A. D. Gruber, and J. Buer. 2010. Inflammation in vivo is modulated by GPR83 isoform-4 but not GPR83 isoform-1 expression in regulatory T cells. Genes Immun. 11: 357-361.

Korber, A., E. N. Schmid, J. Buer, J. Klode, D. Schadendorf, and J. Dissemond. 2010. Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department. J. Eur. Acad. Dermatol. Venereol. 24: 1017-1025.

Menning, A., C.

Loddenkemper, A. M. Westendorf, B. Szilagyi, J. Buer, C. Siewert, A. Hamann, and J. Huehn. 2010. Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation. Eur. J. Immunol. 40: 2539-2548.

Popp, W., J. Buer, P. M. Rath, J. Steinmann, R. Kundt, C. Scheytt, and D. Hansen. 2010. MRSA — aktuelle Entwicklungen, draengende Probleme. Krankenhaus-Hygiene + Infektionsverhütung 32: 144-150.

Probst-Kepper, M., and J. Buer. 2010. FOXP3 and GARP (LRRC32): the master and its minion.

Biol. Direct. 5: 8.

Probst-Kepper, M., R. Balling, and J. Buer. 2010. FOXP3: required but not sufficient. the role of GARP (LRRC32) as a safeguard of the regulatory phenotype. Curr. Mol. Med. 10: 533-539.

Sokolova, V., T. Knuschke, A. Kovtun, J. Buer, M. Epple, and A. M. Westendorf. 2010. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 31: 5627-5633.

Steinmann, J., J.

Buer, and P. M. Rath. 2010. Caspofungin: cross-reactivity in the Aspergillus antigen assay. J. Clin. Microbiol. 48: 2313.

Steinmann, J., J. Huelsewede, J. Buer, and P. M. Rath. 2010. Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. Mycoses.

Trunk, K., B. Benkert, N. Quack, R. Munch, M. Scheer, J. Garbe, L. Jansch, M. Trost, J. Wehland, J. Buer, M. Jahn, M. Schobert, and D. Jahn. 2010. Anaerobic adaptation in Pseudomonas aeruginosa: definition of the Anr and Dnr regulons.

Environ. Microbiol. 12: 1719-1733.

Vernadakis, S., M. Adamzik, M. Heuer, G. Antoch, H. Baba, M. Fiedler, J. Buer, A. Paul, and G. M. Kaiser. 2010. Hemicolectomy for ischemic colitis : A case report of a (H1N1) virus-associated death. Chirurg 81: 841-845.

Westendorf, A. M., D. Fleissner, W. Hansen, and J. Buer. 2010. T cells, dendritic cells and epithelial cells in intestinal homeostasis.

Int. J. Med. Microbiol. 300: 11-18.

2009

Gereke, M., S. Jung, J. Buer, and D. Bruder. 2009. Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells. Am. J. Respir. Crit Care Med. 179: 344-355.

Steinmann, J., J. Buer, P. M. Rath, A. Paul, and F. Saner. 2009. Invasive aspergillosis in two liver transplant recipients: diagnosis by SeptiFast. Transpl. Infect. Dis. Trehanpati, N., R. Geffers, S.

Hissar, P. Riese, T. Toepfer, J. Buer, M. Kumar, C. A. Guzman, and S. K. Sarin. 2009. Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 49: 781-790.

Ukena, S. N., C. Koenecke, R. Geffers, T. Fuehner, T. Welte, A. Ganser, J. Buer, and A. Franzke. 2009. T helper type 2 differentiation is associated with induction of antibacterial defense mechanisms in blood lymphocytes of patients with sarcoidosis.

Immunol. Invest 38: 49-66.

Westendorf, A. M., D. Fleissner, L. Groebe, S. Jung, A. D. Gruber, W. Hansen, and J. Buer. 2009. CD4+Foxp3+ regulatory T cell expansion induced by antigen-driven interaction with intestinal epithelial cells independent of local dendritic cells. Gut 58: 211-219.

2008

Veldhoen, M., C. Uyttenhove, S. J. van, H. Helmby, A. Westendorf, J. Buer, B. Martin, C. Wilhelm, and B. Stockinger. 2008. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9: 1341-1346.

Schenk, U., A. M. Westendorf, E. Radaelli, A. Casati, M. Ferro, M. Fumagalli, C.

Verderio, J. Buer, E. Scanziani, and F. Grassi. 2008. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Science Signaling. 1: ra6.

Hansen, W., A. M. Westendorf, and J. Buer. 2008. Regulatory T cells as targets for immunotherapy of autoimmunity and inflammation. Inflamm. Allergy Drug Targets. 7: 217-223.

Westendorf, A. M., D. Fleissner, L. Groebe, S. Jung, A. D. Gruber, W. Hansen, and J. Buer. 2008. CD4+ Foxp3+ regulatory T cell expansion induced by antigen-driven interaction with intestinal epithelial cells independent of local dendritic cells.

Gut (im Druck).

Nickeleit, I., S. Zender, F. Sasse, R. Geffers, G. Brandes, I. Sorensen, H. Steinmetz, S. Kubicka, T. Carlomagno, D. Menche, I. Gutgemann, J. Buer, A. Gossler, M. P. Manns, M. Kalesse, R. Candid, and N. P. Malek. 2008. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 14:23.

Haile, L. A., R. von Wasielewski, J. Gamrekelashvili, C. Krüger, O. Bachmann, A. M. Westendorf, J. Buer, R. Liblau, M. P. Manns, F. Korangy, and T. F. Greten. Myeloid derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.

Gastroenterology 135: 871-81, 881.

Veldhoen, M., K. Hirota, A. M. Westendorf, J. Buer, L. Dumoutier, J. C. Renauld, and B. Stockinger.

2008. The aryl hydrocarbon receptor links T(H)17-cell-mediated autoimmunity to environmental toxins. Nature 453:106.

Reinwald, S., C. Wiethe, A. M. Westendorf, M. Breloer, M. Probst-Kepper, B. Fleischer, A. Steinkasserer, J. Buer, and W. Hansen. 2008. CD83 expression in CD4+ T cells modulates inflammation and autoimmunity.

J. Immunol. 180:5890.

Seifert, O., A. Bayat, R. Geffers, K. Dienus, J. Buer, S. Lofgren, and A. Matussek. 2008. Identification of unique gene expression patterns within diverse lesional sites of keloids. Wound. Repair Regen. 16:254.

Gustafsson, C., J. Mjosberg, A. Matussek, R. Geffers, L. Matthiesen, G. Berg, S. Sharma, J. Buer, and J. Ernerudh. 2008. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype.

PLoS. ONE. 3:e2078.

2007

Bohn, G., A. Allroth, G. Brandes, J. Thiel, E. Glocker, A. A. Schaffer, C. Rathinam, N. Taub, D. Teis, C. Zeidler, R. A. Dewey, R. Geffers, J. Buer, L. A. Huber, K. Welte, B. Grimbacher, and C. Klein. 2007. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat. Med. 13:38.

Choudhury, A. R., Z. Ju, M. W. Djojosubroto, A.

Schienke, A. Lechel, S. Schaetzlein, H. Jiang, A. Stepczynska, C. Wang, J. Buer, H. W. Lee, Z. T. von, A. Ganser, P. Schirmacher, H. Nakauchi, and K. L. Rudolph. 2007. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet. 39:99.

Gereke, M., L. Grobe, S. Prettin, M. Kasper, S. Deppenmeier, A. D. Gruber, R. I. Enelow, J. Buer, and D. Bruder. 2007. Phenotypic alterations in type II alveolar epithelial cells in CD4+ T cell mediated lung inflammation.

Respir. Res. 8:47.

Hansen, W., A. M. Westendorf, S. Reinwald, D. Bruder, S. Deppenmeier, L. Groebe, M. Probst-Kepper, A. D. Gruber, R. Geffers, and J. Buer. 2007. Chronic antigen stimulation in vivo induces a distinct population of antigen-specific Foxp3 CD25 regulatory T cells. J. Immunol. 179:8059.

He, F., J. Buer, A. P. Zeng, and R. Balling. 2007. Dynamic cumulative activity of transcription factors as a mechanism of quantitative gene regulation.

Genome Biol. 8:R181.

Jablonska, J., K. E. Dittmar, T. Kleinke, J. Buer, and S. Weiss. 2007. Essential role of CCL2 in clustering of splenic ERTR-9+ macrophages during infection of BALB/c mice by Listeria monocytogenes. Infect. Immun. 75:462.

Masse, G. X., E. Corcuff, H. Decaluwe, U. Bommhardt, O. Lantz, J. Buer, and J. P. Di Santo. 2007. gamma(c) cytokines provide multiple homeostatic signals to naive CD4(+) T cells.

Eur. J. Immunol. 37:2606.

McMillan, D. J., R. Geffers, J. Buer, B. J. Vlaminckx, K. S. Sriprakash, and G. S. Chhatwal. 2007. Variations in the distribution of genes encoding virulence and extracellular proteins in group A streptococcus are largely restricted to 11 genomic loci. Microbes. Infect. 9:259.

Schrader, A. J., A. Hegele, P. Olbert, J. Buer, A. Jeron, and R. Hofmann. 2007. Observational study of Sorafenib in papillary renal cell carcinoma. Urologe A 46:1291.

Stecher, B., R. Robbiani, A. W. Walker, A. M. Westendorf, M. Barthel, M. Kremer, S. Chaffron, A.

J. Macpherson, J. Buer, J. Parkhill, G. Dougan, M. C. von, and W. D. Hardt. 2007. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS. Biol. 5:2177.

Ukena, S. N., A. Singh, U. Dringenberg, R. Engelhardt, U. Seidler, W. Hansen, A. Bleich, D. Bruder, A. Franzke, G. Rogler, S. Suerbaum, J. Buer, F. Gunzer, and A. M. Westendorf. 2007. Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity. PLoS. ONE. 2:e1308.

2006

Blumenthal, A., S. Ehlers, J. Lauber, J. Buer, C. Lange, T. Goldmann, H. Heine, E. Brandt, and N. Reiling. 2006. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation.

Blood 108:965.

Bredenbruch, F., R. Geffers, M. Nimtz, J. Buer, and S. Haussler. 2006. The Pseudomonas aeruginosa quinolone signal (PQS) has an iron-chelating activity. Environ. Microbiol. 8:1318.

de Buhr, M. F., M. Mahler, R. Geffers, W. Hansen, A. M. Westendorf, J. Lauber, J. Buer, B. Schlegelberger, H. J. Hedrich, and A. Bleich. 2006. Cd14, Gbp1, and Pla2g2a: three major candidate genes for experimental IBD identified by combining QTL and microarray analyses.

Physiol Genomics 25:426.

Franzke, A., J. K. Hunger, K. E. Dittmar, A. Ganser, and J. Buer. 2006. Regulatory T-cells in the control of immunological diseases. Ann. Hematol. 85:747.

Franzke, A., R. Geffers, J. K. Hunger, S. Pfortner, W. Piao, P. Ivanyi, J. Grosse, M. Probst-Kepper, A. Ganser, and J. Buer. 2006. Identification of novel regulators in T-cell differentiation of aplastic anemia patients. BMC. Genomics 7:263.

Franzke, A., C. Koenecke, R. Geffers, W. Piao, J. K. Hunger, A. Ganser, and J. Buer. 2006. Classical Hodgkin’s lymphoma: molecular evidence for specific alterations in circulating T lymphocytes.

Tumour. Biol. 27:329.

Fritzsching, B., N. Oberle, E. Pauly, R. Geffers, J. Buer, J. Poschl, P. Krammer, O. Linderkamp, and E. Suri-Payer. 2006. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 108:3371.

Garbe, A. I., B. Vermeer, J. Gamrekelashvili, W. R. von, F. R. Greten, A. M. Westendorf, J. Buer, R. M. Schmid, M. P. Manns, F. Korangy, and T. F. Greten. 2006. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res. 66:508.

Hansen, W., K. Loser, A. M. Westendorf, D. Bruder, S. Pfoertner, C. Siewert, J. Huehn, S. Beissert, and J.

Buer. 2006. G protein-coupled receptor 83 overexpression in naive CD4+CD25- T cells leads to the induction of Foxp3+ regulatory T cells in vivo. J. Immunol. 177:209.

Kaps, C., S. Frauenschuh, M. Endres, J. Ringe, A. Haisch, J. Lauber, J. Buer, V. Krenn, T. Haupl, G. R. Burmester, and M. Sittinger. 2006. Gene expression profiling of human articular cartilage grafts generated by tissue engineering. Biomaterials 27:3617.

McMillan, D. J., R. G. Beiko, R. Geffers, J. Buer, L. M. Schouls, B. J. Vlaminckx, W. J. Wannet, K. S. Sriprakash, and G. S. Chhatwal. 2006. Genes for the majority of group a streptococcal virulence factors and extracellular surface proteins do not confer an increased propensity to cause invasive disease.

Clin. Infect. Dis. 43:884.

Nalca, Y., L. Jansch, F. Bredenbruch, R. Geffers, J. Buer, and S. Haussler. 2006. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 50:1680.

Ocklenburg, F., D. Moharregh-Khiabani, R. Geffers, V. Janke, S. Pfoertner, H. Garritsen, L. Groebe, J. Klempnauer, K. E. Dittmar, S. Weiss, J. Buer, and M. Probst-Kepper. 2006. UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells.

Lab Invest 86:724.

Pfoertner, S., A. Jeron, M. Probst-Kepper, C. A. Guzman, W. Hansen, A. M. Westendorf, T. Toepfer, A. J. Schrader, A. Franzke, J. Buer, and R. Geffers. 2006. Signatures of human regulatory T cells: an encounter with ancient friends and new players. Genome Biol. 7:R54.

Schrader, A. J., Z. Varga, S. Pfoertner, U. Goelden, J. Buer, and R. Hofmann. 2006. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. BJU. Int. 97:461.

Timmerbeul, I., C. M. Garrett-Engele, U. Kossatz, X. Chen, E. Firpo, V. Grunwald, K. Kamino, L. Wilkens, U. Lehmann, J. Buer, R. Geffers, S. Kubicka, M.

P. Manns, P. L. Porter, J. M. Roberts, and N. P. Malek. 2006. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc. Natl. Acad. Sci. U. S. A 103:14009.

Veldman, C., A. Pahl, S. Beissert, W. Hansen, J. Buer, D. Dieckmann, G. Schuler, and M. Hertl. 2006. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells. J. Immunol. 176:3215.

Wendt, K., E.

Wilk, S. Buyny, J. Buer, R. E. Schmidt, and R. Jacobs. 2006. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J. Leukoc. Biol. 80:1529.

Westendorf, A. M., D. Bruder, W. Hansen, and J. Buer. 2006. Intestinal epithelial antigen induces CD4+ T cells with regulatory phenotype in a transgenic autoimmune mouse model. Ann. N. Y. Acad. Sci. 1072:401.

Westendorf, A. M., D. Fleissner, S.

Deppenmeier, A. D. Gruber, D. Bruder, W. Hansen, R. Liblau, and J. Buer. 2006. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells. Gastroenterology 131:510.

2005

Blumenthal, A., J. Lauber, R. Hoffmann, M. Ernst, C. Keller, J. Buer, S. Ehlers, and N. Reiling. 2005. Common and unique gene expression signatures of human macrophages in response to four strains of Mycobacterium avium that differ in their growth and persistence characteristics. Infect. Immun. 73:3330.

Bruder, D., A. M. Westendorf, W.

Hansen, S. Prettin, A. D. Gruber, Y. Qian, H. von Boehmer, K. Mahnke, and J. Buer. 2005. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54:3395.

Buer, J., A. M. Westendorf, A. P. Zeng, F. He, W. Hansen, and M. Probst-Kepper. 2005. Mechanisms of central and peripheral T-cell tolerance: An update. Transfusion Medicine and Hemotherapy 32:384.

Goelden, U., S. Pfoertner, W. Hansen, T. Toepfer, K. R. von, R. Hofmann, J. Buer, and A. J. Schrader. 2005. Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.

Urol. Int. 75:269.

Goelden, U., S. N. Ukena, S. Pfoertner, R. Hofmann, J. Buer, and A. J. Schrader. 2005. RAR-beta(1) overexpression in chromophobe renal cell carcinoma: a novel target for therapeutic intervention? Exp. Oncol. 27:220.

Juhas, M., L. Wiehlmann, P. Salunkhe, J. Lauber, J. Buer, and B. Tummler. 2005. GeneChip expression analysis of the VqsR regulon of Pseudomonas aeruginosa TB. FEMS Microbiol. Lett. 242:287.

Lechel, A., A. Satyanarayana, Z. Ju, R. R. Plentz, S. Schaetzlein, C. Rudolph, L. Wilkens, S. U. Wiemann, G. Saretzki, N. P. Malek, M. P. Manns, J. Buer, and K. L. Rudolph. 2005. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo.

EMBO Rep. 6:275.

Loser, K., W. Hansen, J. Apelt, S. Balkow, J. Buer, and S. Beissert. 2005. In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther. 12:1294.

Matussek, A., J. Strindhall, L. Stark, M. Rohde, R. Geffers, J. Buer, E. Kihlstrom, P. E. Lindgren, and S. Lofgren. 2005. Infection of human endothelial cells with Staphylococcus aureus induces transcription of genes encoding an innate immunity response. Scand. J. Immunol. 61:536.

Pfoertner, S., U. Goelden, W. Hansen, T. Toepfer, R. Geffers, S. N. Ukena, K. R. von, R. Hofmann, J. Buer, and A. J. Schrader.

2005. Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma. Tumour. Biol. 26:313.

Priebe-Richter, C., P. Ivanyi, J. Buer, F. Langer, J. Lotz, B. Hertenstein, A. Ganser, and A. Franzke. 2005. Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. Eur. J. Haematol. 75:68.

Rathinam, C., R. Geffers, R. Yucel, J. Buer, K. Welte, T. Moroy, and C. Klein. 2005. The transcriptional repressor Gfi1 controls STAT3-dependent dendritic cell development and function. Immunity. 22:717.

Rharbaoui, F., D. Bruder, M. Vidakovic, T. Ebensen, J. Buer, and C.

A. Guzman. 2005. Characterization of a B220+ lymphoid cell subpopulation with immune modulatory functions in nasal-associated lymphoid tissues. J. Immunol. 174:1317.

Salunkhe, P., T. Topfer, J. Buer, and B. Tummler. 2005. Genome-wide transcriptional profiling of the steady-state response of Pseudomonas aeruginosa to hydrogen peroxide. J. Bacteriol. 187:2565.

Sun, J., F. Gunzer, A. M. Westendorf, J.

Buer, M. Scharfe, M. Jarek, F. Gossling, H. Blocker, and A. P. Zeng. 2005. Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. J. Biotechnol. 117:147.

Ukena, S. N., A. M. Westendorf, W. Hansen, M. Rohde, R. Geffers, S. Coldewey, S. Suerbaum, J. Buer, and F.

What is aspergillus fumigatus allergy

Gunzer. 2005. The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1. BMC. Med. Genet. 6:43.

Westendorf, A. M., F. Gunzer, S. Deppenmeier, D. Tapadar, J. K. Hunger, M. A. Schmidt, J. Buer, and D. Bruder. 2005. Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol. Med. Microbiol. 43:373.

Westendorf, A. M., M. Templin, R. Geffers, S. Deppenmeier, A. D. Gruber, M. Probst-Kepper, W. Hansen, R. S. Liblau, F. Gunzer, D. Bruder, and J. Buer. 2005. CD4+ T cell mediated intestinal immunity: chronic inflammation versus immune regulation.

Gut 54:60.

Wiemann, S. U., A. Satyanarayana, J. Buer, K. Kamino, M. P. Manns, and K. L. Rudolph. 2005. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. Oncogene 24:1501.

2004

Bohn, E., S. Muller, J. Lauber, R. Geffers, N. Speer, C. Spieth, J. Krejci, B. Manncke, J. Buer, A. Zell, and I. B. Autenrieth. 2004.

Gene expression patterns of epithelial cells modulated by pathogenicity factors of Yersinia enterocolitica. Cell Microbiol. 6:129.

Bruder, D., A. M. Westendorf, R. Geffers, A. D. Gruber, M. Gereke, R. I. Enelow, and J. Buer. 2004. CD4 T Lymphocyte-mediated lung disease: steady state between pathological and tolerogenic immune reactions. Am. J. Respir. Crit Care Med. 170:1145.

Bruder, D., M. Probst-Kepper, A. M. Westendorf, R. Geffers, S. Beissert, K. Loser, H. von Boehmer, J. Buer, and W. Hansen. 2004.

Neuropilin-1: a surface marker of regulatory T cells. Eur. J. Immunol. 34:623.

Eschbach, M., K. Schreiber, K. Trunk, J. Buer, D. Jahn, and M. Schobert. 2004. Long-term anaerobic survival of the opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J. Bacteriol. 186:4596.

Hansen, W., and J. Buer. 2004. Role of regulatory T cells for the outcome of allo- and autoimmune responses. Transfusion Medicine and Hemotherapy 31:322.

Huehn, J., K. Siegmund, J. C. Lehmann, C. Siewert, U. Haubold, M. Feuerer, G. F. Debes, J. Lauber, O. Frey, G. K. Przybylski, U. Niesner, R. M. de la, C.

A. Schmidt, R. Brauer, J. Buer, A. Scheffold, and A. Hamann. 2004. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199:303.

Keller, C., J. Lauber, A. Blumenthal, J. Buer, and S. Ehlers. 2004. Resistance and susceptibility to tuberculosis analysed at the transcriptome level: lessons from mouse macrophages. Tuberculosis. (Edinb. ) 84:144.

Kossatz, U., N.

Dietrich, L. Zender, J. Buer, M. P. Manns, and N. P. Malek. 2004. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18:2602.

Ma, H. W., B. Kumar, U. Ditges, F. Gunzer, J. Buer, and A. P. Zeng. 2004. An extended transcriptional regulatory network of Escherichia coli and analysis of its hierarchical structure and network motifs. Nucleic Acids Res. 32:6643.

Ma, H. W., J. Buer, and A. P. Zeng. 2004. Hierarchical structure and modules in the Escherichia coli transcriptional regulatory network revealed by a new top-down approach.

BMC. Bioinformatics. 5:199.

Rharbaoui, F., A. Westendorf, C. Link, S. Felk, J. Buer, M. Gunzer, and C. A. Guzman. 2004. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect. Immun. 72:6978.

Saravanamuthu, S. S., G. F. von, P. Salunkhe, R. Chozhavendan, R. Geffers, J. Buer, B. Tummler, and I. Steinmetz. 2004. Evidence for polyadenylated mRNA in Pseudomonas aeruginosa. J. Bacteriol. 186:7015.

Satyanarayana, A., R.

Geffers, M. P. Manns, J. Buer, and K. L. Rudolph. 2004. Gene expression profile at the G1/S transition of liver regeneration after partial hepatectomy in mice. Cell Cycle 3:1405.

Satyanarayana, A., R. A. Greenberg, S. Schaetzlein, J. Buer, K. Masutomi, W. C. Hahn, S. Zimmermann, U. Martens, M. P. Manns, and K. L. Rudolph. 2004. Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol. Cell Biol. 24:5459.

Schrader, A. J., K. R. von, A. Heidenreich, J. Buer, and R. Hofmann. 2004. Application of retinoids in the treatment of renal cell carcinoma—a futile effort? Anticancer Drugs 15:819.

von Götz,.

F., S. Haussler, D. Jordan, S. S. Saravanamuthu, D. Wehmhoner, A. Strussmann, J. Lauber, I. Attree, J. Buer, B. Tummler, and I. Steinmetz. 2004. Expression analysis of a highly adherent and cytotoxic little colony variant of Pseudomonas aeruginosa isolated from a lung of a patient with cystic fibrosis. J. Bacteriol. 186:3837.

Walter, U., W. A. Scherbaum, U. Walter, and J. Buer. 2004. MHC class II expression by beta cells in Type 1 diabetes: promoting or inhibiting the autoimmune process? A reply to D. W. R. Gray. Diabetologia 47:1641.

2003

Buer, J., and R. Balling. 2003. Mice, microbes and models of infection.

Nat. Rev. Genet. 4:195.

Franzke, A., W. Piao, J. Lauber, P. Gatzlaff, C. Konecke, W. Hansen, A. Schmitt-Thomsen, B. Hertenstein, J. Buer, and A. Ganser. 2003. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 102:734.

Matussek, A., J. Lauber, A. Bergau, W. Hansen, M. Rohde, K. E. Dittmar, M. Gunzer, M. Mengel, P. Gatzlaff, M. Hartmann, J. Buer, and F. Gunzer. 2003. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells.

Blood 102:1323.

Pulz, M., A. Matussek, M. Monazahian, A. Tittel, E. Nikolic, M. Hartmann, T. Bellin, J. Buer, and F. Gunzer. 2003. Comparison of a shiga toxin enzyme-linked immunosorbent assay and two types of PCR for detection of shiga toxin-producing Escherichia coli in human stool specimens. J. Clin. Microbiol. 41:4671.

Samson, S. I., O. Richard, M.

What is aspergillus fumigatus allergy

Tavian, T. Ranson, C. A. Vosshenrich, F. Colucci, J. Buer, F. Grosveld, I. Godin, and J. P. Di Santo. 2003. GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity. 19:701.

Satyanarayana, A., S. U. Wiemann, J. Buer, J. Lauber, K. E. Dittmar, T. Wustefeld, M. A. Blasco, M. P. Manns, and K. L. Rudolph. 2003. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 22:4003.

Schrader, A. J., J. Lauber, O. Lechner, A. Heidenreich, R. Hofmann, and J. Buer. 2003. Application of real-time reverse transcriptase-polymerase chain reaction in urological oncology.

J. Urol. 169:1858.

Walter, U., T. Toepfer, K. E. Dittmar, K. Kretschmer, J. Lauber, S. Weiss, G. Servos, O. Lechner, W. A. Scherbaum, S. R. Bornstein, H. von Boehmer, and J. Buer. 2003. Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia 46:1106.

Wuestefeld, T., C. Klein, K. L. Streetz, U. Betz, J. Lauber, J. Buer, M. P. Manns, W. Muller, and C. Trautwein. 2003. Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J. Biol. Chem. 278:11281.

2002

Ehlers, S., J. Lehmann, K.

Müller, J. Buer, and J. Lauber. 2002. Measuring immune responses. In Immunology of infection, Vol. 32. S. H. E. Kaufmann and D. Kabelitz, eds. Academic Press, San Diego, pp. 403.

Lechner, O., D. Bruder, J. Lauber, and J. Buer. 2002. Anergic T-cells. Biomed. Progress 15:11.

Lechner, O., D. Bruder, J. Lauber, and J. Buer. 2002.

What is aspergillus fumigatus allergy

Anerge T-Zellen: Immunregulatoren mit Potential für die Klinik! Die gelben Heft 42:17.

Salunkhe, P., F. von Götz, L. Wiehlmann, J. Lauber, J. Buer, and B. Tümmler. 2002. Gene-chip expression analysis of the response of the response of Pseudomonas aeruginosa to paraquat induced superoxide stress. Genome Letters 4:165.

Schrader, A. J., O. Lechner, M. Templin, K. E. Dittmar, S. Machtens, M. Mengel, M. Probst-Kepper, A. Franzke, T. Wollensak, P. Gatzlaff, J. Atzpodien, J. Buer, and J. Lauber. 2002. CXCR4/CXCL12 expression and signalling in kidney cancer.

Br. J. Cancer 86:1250.

Sechi, A. S., J. Buer, J. Wehland, and M. Probst-Kepper. 2002. Changes in actin dynamics at the T-cell/APC interface: implications for T-cell anergy? Immunol. Rev. 189:98.

2001

Felske, A., B. V. Pauling, H. F. von Canstein, Y. Li, J. Lauber, J. Buer, and I. Wagner-Dobler. 2001. Detection of little sequence differences using competitive PCR: molecular monitoring of genetically improved, mercury-reducing bacteria. Biotechniques 30:142.

Franzke, A., J.

Buer, M. Probst-Kepper, C. Lindig, M. Framzle, A. J. Schrader, A. Ganser, and J. Atzpodien. 2001. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother. Radiopharm. 16:401.

Hess, S., C. Rheinheimer, F. Tidow, G. Bartling, C. Kaps, J. Lauber, J. Buer, and A. Klos. 2001. The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes.

Arthritis Rheum. 44:2392.

Lechner, O., J. Lauber, A. Franzke, A. Sarukhan, H. von Boehmer, and J. Buer. 2001. Fingerprints of anergic T cells. Curr. Biol. 11:587. Walter, U., T. Toepfer, J. Lauber, J. Buer, and O. Lechner. 2001. High efficient reverse transcription for single cell multiplex RT PCR. Hybaid Technical Report.

2000

Oevermann, K., J. Buer, R. Hoffmann, A. Franzke, A. Schrader, T. Patzelt, H. Kirchner, and J. Atzpodien. 2000. Capecitabine in the treatment of metastatic renal cell carcinoma.

Br. J. Cancer 83:583.

Schrader, A. J., M. Probst-Kepper, J. Grosse, U. Kunter, F. Schenk, A. Franzke, J. Atzpodien, and J. Buer. 2000.

What is aspergillus fumigatus allergy

Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res. 10:355.

Schrader, A. J., M. Probst-Kepper, J. Grosse, U. Kunter, A. Franzke, S. Sel, E. Atzpodien, and J. Buer. 2000. Tumour microdissemination and survival in metastatic melanoma. Anticancer Res. 20:3619.

Walter, U., A. Franzke, A. Sarukhan, C. Zober, B. H. von, J. Buer, and O. Lechner. 2000. Monitoring gene expression of TNFR family members by beta-cells during development of autoimmune diabetes.

Eur. J. Immunol. 30:1224.

1999

Atzpodien, J., J. Buer, and M. Probst-Kepper. 1999. Therapie des Nierenzellkarzinoms. In Onkologie. H. zur Hausen, ed. EcoMed, Landsberg, pp. 1.

Atzpodien, J., J. Buer, S. Sel, J. Janssen, and K. Oevermann. 1999. Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma. Urologe A 38:474.

Franzke, A., D. Peest, M. Probst-Kepper, J. Buer, G. I. Kirchner, G. Brabant, H. Kirchner, A. Ganser, and J. Atzpodien. 1999. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer.

J. Clin. Oncol. 17:529.

Hoffmann, R., A. Franzke, J. Buer, S. Sel, K. Oevermann, A. Duensing, M. Probst, S. Duensing, H. Kirchner, A. Ganser, and J. Atzpodien. 1999. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br. J. Cancer 79:1742.

von Boehmer, H., I. Aifantis, J. Feinberg, O. Lechner, C. Saint-Ruf, U. Walter, J. Buer, and O. Azogui. 1999. Pleiotropic changes controlled by the pre-T-cell receptor. Curr.

Opin. Immunol. 11:135.

Wittke, F., R. Hoffmann, J. Buer, I. Dallmann, K. Oevermann, S. Sel, T. Wandert, A. Ganser, and J. Atzpodien. 1999. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br. J. Cancer 79:1182.

1998

Aifantis, I., O. Azogui, J. Feinberg, C. Saint-Ruf, J. Buer, and H. von Boehmer. 1998. On the role of the pre-T cell receptor in alphabeta versus gammadelta T lineage commitment. Immunity. 9:649.

Atzpodien, J., J.

Buer, and M. Probst-Kepper. 1998. Nierenzellkarzinom. In Therapiekonzepte Onkologie. S. Seeber and J. Schütte, eds. Springer, Heidelberg, pp. 949.

Atzpodien, J., J. Buer, M. Probst-Kepper, and K. Oevermann. 1998. Immun-Chemotherapie des fortgeschrittenen Nierenzellkarzinoms. In Nierenzellkarzinom. D. Schnoor and S. A. Loening, eds. Blackwell Wissenschaft, Berlin, pp. 160.

Atzpodien, J., J. Buer, S.

Sel, and K. Oevermann. 1998. Interleunkin-2 in renal cell carcinoma. In PACIOU V. F. H. Schröder, ed. Panthenon Publishing.Buer, J., and H. von Boehmer. 1998. How essentiell is the pre-TCR? In The molecular biology of B and T cell development. J. G. Monroe and G. Rothenberg, eds. Humana Press, Totowa, pp. 449.

Buer, J., A. Lanoue, A. Franzke, C. Garcia, H. von Boehmer, and A. Sarukhan. 1998. Interleukin 10 secretion and impaired effector function of major histocompatibility complicated class II-restricted T cells anergized in vivo.

J. Exp. Med. 187:177.

Franzke, A., M. Probst-Kepper, J. Buer, S. Duensing, R. Hoffmann, F. Wittke, M. Volkenandt, A. Ganser, and J. Atzpodien. 1998. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br. J. Cancer 78:40.

Hoffmann, R., I. Muller, K. Neuber, S. Lassmann, J. Buer, M. Probst, K. Oevermann, A. Franzke, H. Kirchner, A. Ganser, and J.

Atzpodien. 1998. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br. J. Cancer 78:1076.

Kirchner, G. I., A. Franzke, J. Buer, W. Beil, M. Probst-Kepper, F. Wittke, K. Overmann, S. Lassmann, R. Hoffmann, H. Kirchner, A. Ganser, and J. Atzpodien. 1998. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br. J. Clin. Pharmacol. 46:5.

Sarukhan, A., A. Lanoue, A. Franzke, N. Brousse, J. Buer, and H. von Boehmer. 1998. Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model.

EMBO J. 17:71.

von Boehmer, H., I. Aifantis, O. Azogui, J. Feinberg, C. Saint-Ruf, C. Zober, C. Garcia, and J. Buer. 1998. Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. Immunol. Rev. 165:111.

1997

Aifantis, I., J. Buer, H. von Boehmer, and O. Azogui. 1997. Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. Immunity. 7:601.

Buer, J., M. Probst, A. Franzke, S. Duensing, J. Haindl, M. Volkenandt, F.

Wittke, R. Hoffmann, A. Ganser, and J. Atzpodien. 1997. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br. J. Cancer 75:1373.

Buer, J., I. Aifantis, J. P. DiSanto, H. J. Fehling, and H. von Boehmer. 1997. Role of diverse T cell receptors in the development of pre-T cells. J. Exp. Med. 185:1541.

Buer, J., M. Probst, S. Duensing, H. Koditz, A. Franzke, I. Dallmann, A. Ganser, and J. Atzpodien. 1997. Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma.

Cancer Biother. Radiopharm. 12:143.

Buer, J., I. Aifantis, J. P. DiSanto, H. J. Fehling, and H. von Boehmer. 1997. T-cell development in the absence of the pre-T-cell receptor. Immunol. Lett. 57:5.

Probst-Kepper, M., A. Schrader, J. Buer, J. Grosse, M. Volkenandt, H. J. Illiger, B. Metzner, J. Kadar, S. Duensing, B. Hertenstein, A. Ganser, and J. Atzpodien. 1997. Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma.

Br. J. Haematol. 98:488.

von Boehmer, H., A. Sarukhan, and J. Buer. 1997. Induction of and save from programmed cell death: A recurrent theme in lymphocyte physiology. Immunologist 5:185.

1996

Deckert, M., A. Franzke, J. Buer, M. Probst, S. Duensing, E. Lopez-Haenninen, H. Kirchner, H. Poliwoda, and J. Atzpodien. 1996. Linomide and interleukin-2 in patients with advanced renal cell carcinoma. Cancer Biother. Radiopharm. 11:319.

Duensing, S., van den Berg-de Ruiter, S. Storkel, H. Kirchner, E. L. Hanninen, J. Buer, H. Poliwoda, and J. Atzpodien. 1996. Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapy.

Tumour. Biol. 17:27.

Duensing, S., N. F. Brevis, N. Meyer, G. Anastassiou, A. Nasarek, J. Grosse, J. Buer, M. Probst, A. Ganser, and J. Alzpodien. 1996. Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. Invasion Metastasis 16:65.

Kunter, U., J. Buer, M. Probst, S. Duensing, I. Dallmann, J. Grosse, H. Kirchner, E. M. Schluepen, M. Volkenandt, A. Ganser, and J. Atzpodien. 1996. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.

J. Natl. Cancer Inst. 88:590.

1995

Atzpodien, J., H. Kirchner, S. Duensing, H. E. Lopez, A. Franzke, J. Buer, M. Probst, P. Anton, and H. Poliwoda. 1995. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J. Urol. 13:174.

Atzpodien, J., A. Schomburg, and J. Buer. 1995. Interleukin-2. In Immunotherapy of cancer. M. Gore and P. Riches, eds. John Wiley and Sons, Chichester, pp. 43.Buer, J., M. Probst, and J. Atzpodien. 1995. Immunotherapy of cancer: Interleukin-2 alone or in combination with other cytokines.

FORUM Trends Exp. Clin. Med. 5:368.

Buer, J., R. Hilse, I. Dallmann, J. Grosse, H. Kirchner, U. Zorn, E. L. Hanninen, A. Franzke, S. Duensing, H. Poliwoda, and . 1995. Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cells. Cytokines Mol. Ther. 1:39.

Buer, J., M. Probst, A. Ganser, and J. Atzpodien. 1995. Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma. J. Clin. Oncol. 13:2679.

Buer, J., M. Probst, and J. Atzpodien. 1995. Molecular diagnosis of neoplasms. N. Engl.

J. Med. 333:193.

Meffert, M., A. Schomburg, E. L. Hanninen, T. Menzel, S. Vocke, I. Dallmann, J. Grosse, S. Duensing, J. Buer, H. Kirchner, H. Poliwoda, and J. Atzpodien. 1995. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2. Anticancer Res. 15:127.

Probst, M., J. Buer, A. Ganser, and J. Atzpodien. 1995. Interleukin-2 in hematology and oncology: State of the art. Cancer J. 8:270.

Probst, M., J. Buer, and J.

Atzpodien. 1995. Genetic abnormalities during transition from Helicobacter-pylori-associated gastritis to low-grade MALToma. Lancet 345:723.

1994

Buer, J., H. Kirchner, A. Schomburg, A. Schuler, M. Manns, E. Lopez-Hanninen, S. Duensing, H. Poliwoda, and J. Atzpodien. 1994. Cytokine-based biotherapy of gastrointestinal tumors. Clin. Investig. 72:526.

Duensing, S., I. Dallmann, J. Grosse, J. Buer, H. E. Lopez, M. Deckert, S. Storkel, H.

Kirchner, H. Poliwoda, and J. Atzpodien. 1994. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 51:309.


RELATED VIDEO: